Referencia número: HY-10570

Nevirapine

(Synonyms: BI-RG 587; NSC 641530; NVP)

8 Cited Publications

Revisión del cliente

Based on 8 publication(s) in Google Scholar

Nevirapine is a non-nucleoside inhibitor of HIV-1 reverse transcriptase used to treat and prevent HIV/AIDS; with a K_i of 270 μM.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 98.19%
No. CAS: 129618-40-2
Fòrmula: C₁₅H₁₄N₄O
Peso molecular:266.30

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Nevirapine Chemical Structure

No. CAS: 129618-40-2

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Ensayo clínico
Chemical Information
Publications (8)
Solvente y solubilidad
- In Vitro
- In Vivo
Protocolo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

Nevirapine is a non-nucleoside inhibitor of HIV-1 reverse transcriptase used to treat and prevent HIV/AIDS; with a K_i of 270 μM^[1].

IC₅₀ & Target

HIV-1

Ver todos los productos específicos de isoformas HIV :

Ver todos los productos específicos de isoformas Parasite :

Cellular Effect

Cell Line	Type	Value	Description	References
C8166	CC₅₀	>749.1 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days Antiviral activity against HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days	[PMID: 21194939]
C8166	IC₅₀	0.04 μM Compound: 1	Inhibitory concentration against cell culture of Human T-cell line c8166 infected with HIV-1 IIIB strain was determined Inhibitory concentration against cell culture of Human T-cell line c8166 infected with HIV-1 IIIB strain was determined	[PMID: 7490732]
C8166	EC₅₀	>100 μM Compound: nevirapine	Ability to inhibit HIV-2 multiplication in acutely infected C8166 cells Ability to inhibit HIV-2 multiplication in acutely infected C8166 cells	[PMID: 9154967]
C8166	CC₅₀	321 μM Compound: nevirapine (2)	Cytotoxic activity was evaluated in CD4+ lymphoblastoid cell line Cytotoxic activity was evaluated in CD4+ lymphoblastoid cell line	10.1016/0960-894X(95)00257-T
C8166	IC₅₀	0.04 μM Compound: nevirapine (2)	Antiviral activity was evaluated by inhibition of HIV-1 replication in CD4+ lymphoblastoid cell line infected with HIV/IIIB strain Antiviral activity was evaluated by inhibition of HIV-1 replication in CD4+ lymphoblastoid cell line infected with HIV/IIIB strain	10.1016/0960-894X(95)00257-T
CCRF-CEM	IC₅₀	0.005 μM Compound: Nevirapine	Antiviral activity against site directed resistant isolate HIV-1 K101E in CEM cells Antiviral activity against site directed resistant isolate HIV-1 K101E in CEM cells	[PMID: 11708913]
CCRF-CEM	IC₅₀	0.008 μM Compound: Nevirapine	Antiviral activity against site directed 4X AZT resistant isolate HIV-1 in CEM cells Antiviral activity against site directed 4X AZT resistant isolate HIV-1 in CEM cells	[PMID: 11708913]
CCRF-CEM	IC₅₀	0.029 μM Compound: Nevirapine	Antiviral activity against site directed wild-type enzyme isolate HIV-1 NL4-3WT in CEM cells Antiviral activity against site directed wild-type enzyme isolate HIV-1 NL4-3WT in CEM cells	[PMID: 11708913]
CCRF-CEM	IC₅₀	0.061 μM Compound: Nevirapine	Antiviral activity against site directed resistant isolate HIV-1 L74V in CEM cells Antiviral activity against site directed resistant isolate HIV-1 L74V in CEM cells	[PMID: 11708913]
CCRF-CEM	IC₅₀	0.07 μM Compound: Nevirapine	Antiviral activity against site directed resistant isolate HIV-1 V179D in CEM cells Antiviral activity against site directed resistant isolate HIV-1 V179D in CEM cells	[PMID: 11708913]
CCRF-CEM	IC₅₀	0.18 μM Compound: Nevirapine	Antiviral activity against site directed resistant isolate HIV-1 L100I in CEM cells Antiviral activity against site directed resistant isolate HIV-1 L100I in CEM cells	[PMID: 11708913]
CCRF-CEM	IC₅₀	0.207 μM Compound: Nevirapine	Antiviral activity against site directed 4X AZT resistant isolate HIV-1 L100I in CEM cells Antiviral activity against site directed 4X AZT resistant isolate HIV-1 L100I in CEM cells	[PMID: 11708913]
CCRF-CEM	IC₅₀	0.222 μM Compound: Nevirapine	Antiviral activity against site directed resistant isolates in HIV-1 A98G CEM cells Antiviral activity against site directed resistant isolates in HIV-1 A98G CEM cells	[PMID: 11708913]
CCRF-CEM	IC₅₀	1.44 μM Compound: Nevirapine	Antiviral activity against site directed resistant isolate HIV-1 K103N in CEM cells Antiviral activity against site directed resistant isolate HIV-1 K103N in CEM cells	[PMID: 11708913]
CCRF-CEM	IC₅₀	1.88 μM Compound: Nevirapine	Antiviral activity against site directed resistant isolate HIV-1 V106A in CEM cells Antiviral activity against site directed resistant isolate HIV-1 V106A in CEM cells	[PMID: 11708913]
CCRF-CEM	IC₅₀	8.27 μM Compound: Nevirapine	Antiviral activity against site directed resistant isolate HIV-1 Y181C in CEM cells Antiviral activity against site directed resistant isolate HIV-1 Y181C in CEM cells	[PMID: 11708913]
CCRF-CEM	IC₅₀	8.3 μM Compound: Nevirapine	Antiviral activity against site directed resistant isolate HIV-1 Y188C in CEM cells Antiviral activity against site directed resistant isolate HIV-1 Y188C in CEM cells	[PMID: 11708913]
CCRF-CEM	EC₅₀	>75 μM Compound: nevirapine	Antiviral activity against HIV1 with reverse transcriptase Y188H mutation in CEM cells assessed as inhibition of virus-induced giant cell formation Antiviral activity against HIV1 with reverse transcriptase Y188H mutation in CEM cells assessed as inhibition of virus-induced giant cell formation	[PMID: 17276064]
CCRF-CEM	EC₅₀	0.03 μM Compound: nevirapine	Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of virus-induced giant cell formation Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of virus-induced giant cell formation	[PMID: 17276064]
CCRF-CEM	EC₅₀	0.199 μM Compound: nevirapine	Antiviral activity against HIV1 with reverse transcriptase L100I mutation in CEM cells assessed as inhibition of virus-induced giant cell formation Antiviral activity against HIV1 with reverse transcriptase L100I mutation in CEM cells assessed as inhibition of virus-induced giant cell formation	[PMID: 17276064]
CCRF-CEM	EC₅₀	0.207 μM Compound: nevirapine	Antiviral activity against HIV1 with reverse transcriptase E138K mutation in CEM cells assessed as inhibition of virus-induced giant cell formation Antiviral activity against HIV1 with reverse transcriptase E138K mutation in CEM cells assessed as inhibition of virus-induced giant cell formation	[PMID: 17276064]
CCRF-CEM	EC₅₀	1.3 μM Compound: nevirapine	Antiviral activity against HIV1 with reverse transcriptase K103N mutation in CEM cells assessed as inhibition of virus-induced giant cell formation Antiviral activity against HIV1 with reverse transcriptase K103N mutation in CEM cells assessed as inhibition of virus-induced giant cell formation	[PMID: 17276064]
CCRF-CEM	EC₅₀	2.5 μM Compound: nevirapine	Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in CEM cells assessed as inhibition of virus-induced giant cell formation Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in CEM cells assessed as inhibition of virus-induced giant cell formation	[PMID: 17276064]
CCRF-CEM	CC₅₀	>50 μM Compound: nevirapine	Cytotoxicity against CEM cells Cytotoxicity against CEM cells	[PMID: 17321639]
CCRF-CEM	EC₅₀	>50 μM Compound: nevirapine	Antiviral activity against HIV2 ROD in CEM cells Antiviral activity against HIV2 ROD in CEM cells	[PMID: 17321639]
CCRF-CEM	EC₅₀	0.12 μM Compound: nevirapine	Antiviral activity against HIV1 3B in CEM cells Antiviral activity against HIV1 3B in CEM cells	[PMID: 17321639]
CCRF-CEM	EC₅₀	0.035 μM Compound: nevirapine	Antiviral activity against HIV1 infected CEM cells Antiviral activity against HIV1 infected CEM cells	[PMID: 17663538]
CCRF-CEM	CC₅₀	>4 μM Compound: Nevirapine	Cytotoxicity against human CEM cells by MTT assay Cytotoxicity against human CEM cells by MTT assay	[PMID: 18242784]
CCRF-CEM	EC₅₀	0.01 μM Compound: Nevirapine	Antiviral activity against HIV1 3B replication in human CEM cells assessed as inhibition of virus-induced cytopathic effect after 5 days by tetrazolium-based colorimetric assay Antiviral activity against HIV1 3B replication in human CEM cells assessed as inhibition of virus-induced cytopathic effect after 5 days by tetrazolium-based colorimetric assay	[PMID: 18242784]
CCRF-CEM	CC₅₀	>50 μM Compound: nevirapine	Cytotoxicity against HIV-infected human CEM cells Cytotoxicity against HIV-infected human CEM cells	[PMID: 18420310]
CCRF-CEM	EC₅₀	>50 μM Compound: nevirapine	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days	[PMID: 18420310]
CCRF-CEM	EC₅₀	0.12 μM Compound: nevirapine	Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days	[PMID: 18420310]
CCRF-CEM	IC₅₀	24 nM Compound: Nevirapine	Antiviral activity against HIV1 infected in human CEM cells Antiviral activity against HIV1 infected in human CEM cells	[PMID: 18800765]
CCRF-CEM	IC₅₀	>10000 nM Compound: NVP	Antiviral activity against HIV1 with reverse transcriptase Y181I mutation in human CEM cells assessed as protection against virus-induced cytopathicity Antiviral activity against HIV1 with reverse transcriptase Y181I mutation in human CEM cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
CCRF-CEM	IC₅₀	>10000 nM Compound: NVP	Antiviral activity against HIV1 with reverse transcriptase Y188L mutation in human CEM cells assessed as protection against virus-induced cytopathicity Antiviral activity against HIV1 with reverse transcriptase Y188L mutation in human CEM cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
CCRF-CEM	IC₅₀	11000 nM Compound: NVP	Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in human CEM cells assessed as protection against virus-induced cytopathicity Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in human CEM cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
CCRF-CEM	IC₅₀	2900 nM Compound: NVP	Antiviral activity against HIV1 with reverse transcriptase K103N mutation in human CEM cells assessed as protection against virus-induced cytopathicity Antiviral activity against HIV1 with reverse transcriptase K103N mutation in human CEM cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
CCRF-CEM	IC₅₀	60 nM Compound: NVP	Antiviral activity against HIV1 with reverse transcriptase L100I mutation in human CEM cells assessed as protection against virus-induced cytopathicity Antiviral activity against HIV1 with reverse transcriptase L100I mutation in human CEM cells assessed as protection against virus-induced cytopathicity	[PMID: 19281225]
CCRF-CEM	CC₅₀	>10000 μM Compound: NVP	Cytotoxicity against human CEM cells by coulter counter analysis Cytotoxicity against human CEM cells by coulter counter analysis	[PMID: 21366296]
CCRF-CEM	EC₅₀	>10000 nM Compound: NVP	Antiviral activity against HIV2 isolate ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days by microscopic analysis Antiviral activity against HIV2 isolate ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days by microscopic analysis	[PMID: 21366296]
CCRF-CEM	EC₅₀	19.2 nM Compound: NVP	Antiviral activity against wild type HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days by microscopic analysis Antiviral activity against wild type HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days by microscopic analysis	[PMID: 21366296]
CCRF-CEM	EC₅₀	>10000 nM Compound: NVP	Antiviral activity against HIV-2 ROD infected in human CEM cells assessed as protection of cells monitored by giant cell formation by microscopy Antiviral activity against HIV-2 ROD infected in human CEM cells assessed as protection of cells monitored by giant cell formation by microscopy	[PMID: 24769348]
CCRF-CEM	EC₅₀	19.2 nM Compound: NVP	Antiviral activity against HIV1 3B infected in human CEM cells assessed as protection of cells monitored by giant cell formation by microscopy Antiviral activity against HIV1 3B infected in human CEM cells assessed as protection of cells monitored by giant cell formation by microscopy	[PMID: 24769348]
CCRF-CEM	EC₅₀	>10000 nM Compound: NVP	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as protection against virus-induced cytopathicity by giant cell formation assay Antiviral activity against HIV2 ROD infected in human CEM cells assessed as protection against virus-induced cytopathicity by giant cell formation assay	[PMID: 25418038]
CCRF-CEM	EC₅₀	19.2 nM Compound: NVP	Antiviral activity against HIV1 3B infected in human CEM cells assessed as protection against virus-induced cytopathicity by giant cell formation assay Antiviral activity against HIV1 3B infected in human CEM cells assessed as protection against virus-induced cytopathicity by giant cell formation assay	[PMID: 25418038]
CCRF-CEM	CC₅₀	>100 μM Compound: NVP	Cytotoxicity against HIV1 infected human CEM cells assessed as reduction in cell viability after 7 days by MTT assay Cytotoxicity against HIV1 infected human CEM cells assessed as reduction in cell viability after 7 days by MTT assay	[PMID: 27390064]
CCRF-CEM	EC₅₀	>80 μM Compound: Nevirapine	Tested for the inhibitory activity of virus induced giant cell formation in HIV-2 infected CEM cells Tested for the inhibitory activity of virus induced giant cell formation in HIV-2 infected CEM cells	[PMID: 7527463]
CCRF-CEM	EC₅₀	0.11 μM Compound: Nevirapine	Tested for the inhibitory activity of virus induced giant cell formation in HIV-1 infected CEM cells Tested for the inhibitory activity of virus induced giant cell formation in HIV-1 infected CEM cells	[PMID: 7527463]
CCRF-CEM	IC₅₀	84 nM Compound: nevirapine	Inhibitory activity against the HIV-1 in CEM cells Inhibitory activity against the HIV-1 in CEM cells	[PMID: 8676342]
CCRF-CEM	CC₅₀	>25 μM Compound: NVP	Cytotoxicity against human CEM cells after 3 days Cytotoxicity against human CEM cells after 3 days	10.1039/C3MD00036B
CCRF-CEM	EC₅₀	0.024 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human CEM cells assessed as reduction of giant cell formation after 4 days by microscopic analysis Antiviral activity against HIV1 3B infected in human CEM cells assessed as reduction of giant cell formation after 4 days by microscopic analysis	10.1039/C3MD00036B
CEM-SS	EC₅₀	0.015 μM Compound: nevirapine	Antiviral activity against HIV1 RF in human CEM-SS cells by XTT assay Antiviral activity against HIV1 RF in human CEM-SS cells by XTT assay	[PMID: 17803290]
CEM-SS	EC₅₀	0.0015 μM Compound: Nevirapine	Antiviral activity against HIV1RF infected in human CEM-SS cells Antiviral activity against HIV1RF infected in human CEM-SS cells	[PMID: 18083556]
CEM-SS	EC₅₀	0.0015 μM Compound: nevirapine	Antiviral activity against HIV1 RF in CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay Antiviral activity against HIV1 RF in CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay	[PMID: 18222088]
CEM-SS	EC₅₀	0.6 μM Compound: nevirapine	Antiviral activity against NNRTI-resistant HIV1 NL4-3 with reverse transcriptase K103N mutation infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay Antiviral activity against NNRTI-resistant HIV1 NL4-3 with reverse transcriptase K103N mutation infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay	[PMID: 19775161]
CEM-SS	EC₅₀	0.8 μM Compound: nevirapine	Antiviral activity against NNRTI-resistant HIV1 NL4-3 with reverse transcriptase Y181C mutation infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay Antiviral activity against NNRTI-resistant HIV1 NL4-3 with reverse transcriptase Y181C mutation infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay	[PMID: 19775161]
CEM-SS	EC₅₀	>1 μM Compound: NVP	Antiviral activity against HIV1 NL4-3 containing reverse transcriptase K103N mutation infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HIV1 NL4-3 containing reverse transcriptase K103N mutation infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 20888224]
CEM-SS	EC₅₀	>1 μM Compound: NVP	Antiviral activity against HIV1 NL4-3 containing reverse transcriptase Y181C mutation infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against HIV1 NL4-3 containing reverse transcriptase Y181C mutation infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 20888224]
CEM-SS	EC₅₀	0.2 μM Compound: NVP	Antiviral activity against wild type HIV1 NL4-3 infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect Antiviral activity against wild type HIV1 NL4-3 infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect	[PMID: 20888224]
H9	IC₅₀	5 μM Compound: Nevirapine	Inhibitory activity against multidrug resistant HIV-1 strain RT-MDR Inhibitory activity against multidrug resistant HIV-1 strain RT-MDR	[PMID: 10999473]
H9	IC₅₀	0.11 ng/mL Compound: NEV	Inhibition of HIV1 3B reverse transcriptase activity infected in human H9 cells assessed as level of p24 antigen Inhibition of HIV1 3B reverse transcriptase activity infected in human H9 cells assessed as level of p24 antigen	[PMID: 21334901]
H9	EC₅₀	>100 μM Compound: nevirapine	Ability to inhibit HIV-1 multiplication in chronically infected H9/IIIB cells Ability to inhibit HIV-1 multiplication in chronically infected H9/IIIB cells	[PMID: 9154967]
HEK293	CC₅₀	>10 μM Compound: nevirapine	Cytotoxicity against HEK293T cells Cytotoxicity against HEK293T cells	[PMID: 16464578]
HEK293	CC₅₀	>10 μM Compound: nevirapine	Cytotoxicity against HEK293T cells Cytotoxicity against HEK293T cells	[PMID: 16480865]
HEK293	CC₅₀	>10 μM Compound: NVP	Cytotoxicity against HEK293T cells Cytotoxicity against HEK293T cells	[PMID: 16632349]
HEK293	CC₅₀	>10 μM Compound: nevirapine	Cytotoxicity against HEK293T cells Cytotoxicity against HEK293T cells	[PMID: 16782337]
HEK-293T	EC₅₀	0.05 μM Compound: nevirapine	Antiviral activity against HIV1 in HEK293T cells Antiviral activity against HIV1 in HEK293T cells	[PMID: 16464578]
HEK-293T	EC₅₀	0.05 μM Compound: nevirapine	Antiviral activity against HIV1 in HEK293T cells Antiviral activity against HIV1 in HEK293T cells	[PMID: 16480865]
HEK-293T	CC₅₀	>10 μM Compound: nevirapine	Cytotoxicity against HEK293T cells after 48 hrs Cytotoxicity against HEK293T cells after 48 hrs	[PMID: 17035019]
HEK-293T	EC₅₀	0.05 μM Compound: nevirapine	Antiviral activity against HIV in HEK293T cells after 48 hrs Antiviral activity against HIV in HEK293T cells after 48 hrs	[PMID: 17035019]
HEK-293T	CC₅₀	>100 μM Compound: NVP	Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method	[PMID: 17470654]
HEK-293T	IC₅₀	>10 μM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase K103N/G190A double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against HIV1 harboring reverse transcriptase K103N/G190A double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 25072874]
HEK-293T	IC₅₀	>10 μM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 25072874]
HEK-293T	IC₅₀	0.031 μM Compound: NVP	Antiviral activity against wild type HIV1 infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against wild type HIV1 infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 25072874]
HEK-293T	IC₅₀	16.1 μM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 25072874]
HEK-293T	IC₅₀	2.8 μM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase K103N/V108I double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against HIV1 harboring reverse transcriptase K103N/V108I double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 25072874]
HEK-293T	IC₅₀	5 μM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase L1001/K103N double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against HIV1 harboring reverse transcriptase L1001/K103N double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 25072874]
HEK-293T	IC₅₀	5.48 μM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase K103N/P225H double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against HIV1 harboring reverse transcriptase K103N/P225H double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 25072874]
HEK-293T	IC₅₀	66.7 μM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	[PMID: 25072874]
HEK-293T	IC₅₀	0.12 μM Compound: Nevirapine	Antiviral activity against HIV1 infected in HEK293T cells by p24 ELISA based phenotypic assay Antiviral activity against HIV1 infected in HEK293T cells by p24 ELISA based phenotypic assay	[PMID: 25176191]
HEK-293T	IC₅₀	0.05 μM Compound: Nevirapine	Antiviral activity against VSV-G protein pseudotyped HIV1 system in HEK293T cells assessed as reduction in p24 level after 48 hrs by ELISA Antiviral activity against VSV-G protein pseudotyped HIV1 system in HEK293T cells assessed as reduction in p24 level after 48 hrs by ELISA	[PMID: 25495797]
HEK-293T	IC₅₀	0.091 μM Compound: NVP	Inhibition of HIV reverse transcriptase transfected in HEK293T cells assessed as reduction in viral replication measured at 48 hrs postinfection by luciferase reporter based single-cycle non replicative phenotypic assay Inhibition of HIV reverse transcriptase transfected in HEK293T cells assessed as reduction in viral replication measured at 48 hrs postinfection by luciferase reporter based single-cycle non replicative phenotypic assay	[PMID: 27287366]
HEK-293T	IC₅₀	>10 μM Compound: NVP	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/G190A double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/G190A double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	[PMID: 27484516]
HEK-293T	IC₅₀	>10 μM Compound: NVP	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/Y181C double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/Y181C double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	[PMID: 27484516]
HEK-293T	IC₅₀	>10 μM Compound: NVP	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/Y188L double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/Y188L double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	[PMID: 27484516]
HEK-293T	IC₅₀	>10 μM Compound: NVP	Antiviral activity against HIV-1 NL4-3 harboring RT-Y188L mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene Antiviral activity against HIV-1 NL4-3 harboring RT-Y188L mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene	[PMID: 27484516]
HEK-293T	IC₅₀	0.031 μM Compound: NVP	Antiviral activity against wild-type HIV-1 NL4-3 harboring vesicular stomatitis virus glycoprotein infected in HEK293T cells pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene assay Antiviral activity against wild-type HIV-1 NL4-3 harboring vesicular stomatitis virus glycoprotein infected in HEK293T cells pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene assay	[PMID: 27484516]
HEK-293T	IC₅₀	16.1 μM Compound: NVP	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene Antiviral activity against HIV-1 NL4-3 harboring RT-K103N mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene	[PMID: 27484516]
HEK-293T	IC₅₀	2.8 μM Compound: NVP	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/V108I double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/V108I double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	[PMID: 27484516]
HEK-293T	IC₅₀	5 μM Compound: NVP	Antiviral activity against HIV-1 NL4-3 harboring RT-L100I/K103N double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase Antiviral activity against HIV-1 NL4-3 harboring RT-L100I/K103N double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	[PMID: 27484516]
HEK-293T	IC₅₀	5.48 μM Compound: NVP	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/P225H double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/P225H double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	[PMID: 27484516]
HEK-293T	IC₅₀	66.7 μM Compound: NVP	Antiviral activity against HIV-1 NL4-3 harboring RT-Y181C mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene Antiviral activity against HIV-1 NL4-3 harboring RT-Y181C mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene	[PMID: 27484516]
HEK-293T	CC₅₀	92.7 μM Compound: NVP	Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 48 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 48 hrs by CellTiter 96 aqueous one solution assay	[PMID: 30783503]
HEK-293T	CC₅₀	23.72 μM Compound: Nevirapine	Cytotoxicity against human HEK 293T cells assessed as reduction in cell viability measured after 48 hrs by Celltiter-glo assay Cytotoxicity against human HEK 293T cells assessed as reduction in cell viability measured after 48 hrs by Celltiter-glo assay	[PMID: 32004936]
HeLa	IC₅₀	~ 10 μM Compound: NEV	Antiviral activity against V106A mutant virus in the HeLa MAGI assay. Antiviral activity against V106A mutant virus in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	>10 μM Compound: NEV	Antiviral activity against G190A mutant virus in the HeLa MAGI assay. Antiviral activity against G190A mutant virus in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	>10 μM Compound: NEV	Antiviral activity against V106A/Y181C mutant virus in the HeLa MAGI assay. Antiviral activity against V106A/Y181C mutant virus in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	>10 μM Compound: NEV	Antiviral activity against V108I/Y181C mutant virus in the HeLa MAGI assay. Antiviral activity against V108I/Y181C mutant virus in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	>10 μM Compound: NEV	Antiviral activity against Y181C mutant virus in the HeLa MAGI assay. Antiviral activity against Y181C mutant virus in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	>50 μM Compound: NEV	Antiviral activity against K103N/Y181C mutant virus in the HeLa MAGI assay. Antiviral activity against K103N/Y181C mutant virus in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	0.056 μM Compound: NEV	Antiviral activity against P236L mutant virus in the HeLa MAGI assay. Antiviral activity against P236L mutant virus in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	0.072 μM Compound: NEV	Antiviral activity against E138K mutant virus in the HeLa MAGI assay. Antiviral activity against E138K mutant virus in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	0.089 μM Compound: NEV	Antiviral activity against wild-type HIV-1 in the HeLa MAGI assay. Antiviral activity against wild-type HIV-1 in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	0.34 μM Compound: NEV	Antiviral activity against V108I mutant virus in the HeLa MAGI assay. Antiviral activity against V108I mutant virus in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	10 μM Compound: NEV	Antiviral activity against K103N/L100I mutant virus in the HeLa MAGI assay. Antiviral activity against K103N/L100I mutant virus in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	10 μM Compound: NEV	Antiviral activity against K103N/P225H mutant virus in the HeLa MAGI assay. Antiviral activity against K103N/P225H mutant virus in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	2.2 μM Compound: NEV	Antiviral activity against Y188C mutant virus in the HeLa MAGI assay. Antiviral activity against Y188C mutant virus in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	21 μM Compound: NEV	Antiviral activity against K103N/V108I mutant virus in the HeLa MAGI assay. Antiviral activity against K103N/V108I mutant virus in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	7.1 μM Compound: NEV	Antiviral activity against K103N mutant virus in the HeLa MAGI assay. Antiviral activity against K103N mutant virus in the HeLa MAGI assay.	[PMID: 11384233]
HeLa	IC₅₀	~ 10000 nM Compound: Neviripine	Inhibitory concentration against human immunodeficiency virus type 1 (with V106A resistant mutation) was determined in HeLa-CD4 MAGI assay Inhibitory concentration against human immunodeficiency virus type 1 (with V106A resistant mutation) was determined in HeLa-CD4 MAGI assay	[PMID: 15537347]
HeLa	IC₅₀	>10000 nM Compound: Neviripine	Inhibitory concentration against human immunodeficiency virus type 1 (with G190A resistant mutation) was determined in HeLa-CD4 MAGI assay Inhibitory concentration against human immunodeficiency virus type 1 (with G190A resistant mutation) was determined in HeLa-CD4 MAGI assay	[PMID: 15537347]
HeLa	IC₅₀	>10000 nM Compound: Neviripine	Inhibitory concentration against human immunodeficiency virus type 1 (with V106A/Y181C resistant mutation) was determined in HeLa-CD4 MAGI assay Inhibitory concentration against human immunodeficiency virus type 1 (with V106A/Y181C resistant mutation) was determined in HeLa-CD4 MAGI assay	[PMID: 15537347]
HeLa	IC₅₀	>10000 nM Compound: Neviripine	Inhibitory concentration against human immunodeficiency virus type 1 (with V108I/Y181C resistant mutation) was determined in HeLa-CD4 MAGI assay Inhibitory concentration against human immunodeficiency virus type 1 (with V108I/Y181C resistant mutation) was determined in HeLa-CD4 MAGI assay	[PMID: 15537347]
HeLa	IC₅₀	>10000 nM Compound: Neviripine	Inhibitory concentration against human immunodeficiency virus type 1 (with Y181C resistant mutation) was determined in HeLa-CD4 MAGI assay Inhibitory concentration against human immunodeficiency virus type 1 (with Y181C resistant mutation) was determined in HeLa-CD4 MAGI assay	[PMID: 15537347]
HeLa	IC₅₀	>50000 nM Compound: Neviripine	Inhibitory concentration against human immunodeficiency virus type 1 (with K103N/Y181C resistant mutation) was determined in HeLa-CD4 MAGI assay Inhibitory concentration against human immunodeficiency virus type 1 (with K103N/Y181C resistant mutation) was determined in HeLa-CD4 MAGI assay	[PMID: 15537347]
HeLa	IC₅₀	21000 nM Compound: Neviripine	Inhibitory concentration against human immunodeficiency virus type 1 (with K103N/V108I resistant mutation) was determined in HeLa-CD4 MAGI assay Inhibitory concentration against human immunodeficiency virus type 1 (with K103N/V108I resistant mutation) was determined in HeLa-CD4 MAGI assay	[PMID: 15537347]
HeLa	IC₅₀	2200 nM Compound: Neviripine	Inhibitory concentration against human immunodeficiency virus type 1 (with Y188C resistant mutation) was determined in HeLa-CD4 MAGI assay Inhibitory concentration against human immunodeficiency virus type 1 (with Y188C resistant mutation) was determined in HeLa-CD4 MAGI assay	[PMID: 15537347]
HeLa	IC₅₀	340 nM Compound: Neviripine	Inhibitory concentration against human immunodeficiency virus type 1 (with V108I resistant mutation) was determined in HeLa-CD4 MAGI assay Inhibitory concentration against human immunodeficiency virus type 1 (with V108I resistant mutation) was determined in HeLa-CD4 MAGI assay	[PMID: 15537347]
HeLa	IC₅₀	7100 nM Compound: Neviripine	Inhibitory concentration against human immunodeficiency virus type 1 (with K103N resistant mutation) was determined in HeLa-CD4 MAGI assay Inhibitory concentration against human immunodeficiency virus type 1 (with K103N resistant mutation) was determined in HeLa-CD4 MAGI assay	[PMID: 15537347]
HeLa	IC₅₀	>2000 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190A mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190A mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	>2000 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190S mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190S mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	>2000 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	>2000 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/G190A mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/G190A mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	>2000 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/L100I mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/L100I mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	>2000 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/P225H mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/P225H mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	>2000 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/V108I mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/V108I mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	>2000 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/Y181C mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/Y181C mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	>2000 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A/Y181C mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A/Y181C mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	>2000 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I/Y181C mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I/Y181C mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	>2000 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106M mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106M mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	>2000 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I/Y181C mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I/Y181C mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	>2000 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y181C mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y181C mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	>2000 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188L mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188L mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	118 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P225H mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P225H mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	1868 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	294 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	304 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase L100I mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase L100I mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	409 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K101E mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K101E mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	53 nM Compound: nevirapine, NVP	Antiviral activity against wild type HIV1 in HeLa cells by MAGI assay Antiviral activity against wild type HIV1 in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	59 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P236L mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P236L mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	71 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase E138K mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase E138K mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	801 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188C mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188C mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	83 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190E mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190E mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	IC₅₀	89 nM Compound: nevirapine, NVP	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I mutant in HeLa cells by MAGI assay Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I mutant in HeLa cells by MAGI assay	[PMID: 18665583]
HeLa	CC₅₀	>4 μM Compound: Nevirapine	Cytotoxicity against mock-infected human HeLa cells by MTT assay Cytotoxicity against mock-infected human HeLa cells by MTT assay	[PMID: 25682562]
HuT78	CC₅₀	>14 μM Compound: Nevirapine	Cytotoxicity against human HUT78 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human HUT78 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 26613134]
HuT78	EC₅₀	0.26 μM Compound: Nevirapine	Antiviral activity against HIV1 3B persistently infected in HUT78 cells assessed as reduction of p24 production after 43 hrs by ELISA Antiviral activity against HIV1 3B persistently infected in HUT78 cells assessed as reduction of p24 production after 43 hrs by ELISA	[PMID: 26613134]
Jurkat	CC₅₀	>2 μg/mL Compound: Nevirapine	Cytotoxicity against human Jurkat A72 cells by MTT assay Cytotoxicity against human Jurkat A72 cells by MTT assay	[PMID: 20377249]
Jurkat	EC₅₀	<0.2 μg/mL Compound: Nevirapine	Antiviral activity against HIV S056 infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry Antiviral activity against HIV S056 infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry	[PMID: 20377249]
Jurkat	EC₅₀	>2 μg/mL Compound: Nevirapine	Antiviral activity against HIV2 ROD infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry Antiviral activity against HIV2 ROD infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry	[PMID: 20377249]
Jurkat	EC₅₀	0.005 μg/mL Compound: Nevirapine	Antiviral activity against AZT-resistant HIV infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry Antiviral activity against AZT-resistant HIV infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry	[PMID: 20377249]
Jurkat	EC₅₀	0.008 μg/mL Compound: Nevirapine	Antiviral activity against HIV1 3B infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry Antiviral activity against HIV1 3B infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry	[PMID: 20377249]
Jurkat	EC₅₀	0.008 μg/mL Compound: Nevirapine	Antiviral activity against HIV1 NL4-3 infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry Antiviral activity against HIV1 NL4-3 infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry	[PMID: 20377249]
Jurkat	EC₅₀	0.012 μg/mL Compound: Nevirapine	Antiviral activity against HIV S07 infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry Antiviral activity against HIV S07 infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry	[PMID: 20377249]
Jurkat	EC₅₀	0.016 μg/mL Compound: Nevirapine	Antiviral activity against HIV S067 infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry Antiviral activity against HIV S067 infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry	[PMID: 20377249]
Jurkat	IC₅₀	40 nM Compound: Nevirapine	Antiviral activity against HIV1 Env-pseudovirus infected in human Jurkat E6-1 cells after 2 days by luciferase assay Antiviral activity against HIV1 Env-pseudovirus infected in human Jurkat E6-1 cells after 2 days by luciferase assay	[PMID: 21414776]
Lymphocyte	EC₅₀	0.038 μg/mL Compound: BI-RG-587	Concentration required to inhibit HIV-1 induced cytopathicity in human MT-4 lymphocyte cells. Concentration required to inhibit HIV-1 induced cytopathicity in human MT-4 lymphocyte cells.	[PMID: 1495006]
MOLT-3	CC₅₀	20.06 μg/mL Compound: NEV	Cytotoxicity against human MOLT3 cells after 24 hrs by MTS assay Cytotoxicity against human MOLT3 cells after 24 hrs by MTS assay	[PMID: 21334901]
MRC5	IC₅₀	>64 μM Compound: Nevirapine	Cytotoxicity against human MRC5 SV2 cells assessed as reduction in cell growth after 72 hrs Cytotoxicity against human MRC5 SV2 cells assessed as reduction in cell growth after 72 hrs	[PMID: 25199582]
MRC5	IC₅₀	>64 μM Compound: Nevirapine	Trypanocidal activity against nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 infected in human MRC5 SV2 cells assessed as parasite growth inhibition after 168 hrs by beta-galactosidase assay Trypanocidal activity against nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 infected in human MRC5 SV2 cells assessed as parasite growth inhibition after 168 hrs by beta-galactosidase assay	[PMID: 25199582]
MT2	CC₅₀	>10 μM Compound: Nevirapine	Cytotoxicity against MT2 cells Cytotoxicity against MT2 cells	[PMID: 16263277]
MT2	CC₅₀	>10 μM Compound: Nevirapine	Cytotoxicity against human MT2 cells by MTT assay Cytotoxicity against human MT2 cells by MTT assay	[PMID: 16298131]
MT2	EC₅₀	0.12 μM Compound: Nevirapine	Antiviral activity against HIV1 3B in MT2 cells by MTT assay Antiviral activity against HIV1 3B in MT2 cells by MTT assay	[PMID: 16298131]
MT2	CC₅₀	>10 μM Compound: nevirapine	Cytotoxicity against MT2 cells Cytotoxicity against MT2 cells	[PMID: 16931015]
MT2	EC₅₀	0.11 μM Compound: nevirapine	Antiviral activity against HIV1 3B in MT2 cells Antiviral activity against HIV1 3B in MT2 cells	[PMID: 16931015]
MT2	CC₅₀	>10 μM Compound: nevirapine	Cytotoxicity against human MT2 cells by MTT assay Cytotoxicity against human MT2 cells by MTT assay	[PMID: 17918923]
MT2	EC₅₀	0.11 μM Compound: nevirapine	Antiviral activity against HIV1 3B in human MT2 cells by MTT assay Antiviral activity against HIV1 3B in human MT2 cells by MTT assay	[PMID: 17918923]
MT2	EC₅₀	>14.8 μM Compound: nevirapine	Antiviral activity against multidrug-resistant HIV1 with reverse transcriptase 41L, 67N, 210W, 215Y, 184V, 103N mutation infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA Antiviral activity against multidrug-resistant HIV1 with reverse transcriptase 41L, 67N, 210W, 215Y, 184V, 103N mutation infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	[PMID: 19053755]
MT2	EC₅₀	>14.8 μM Compound: nevirapine	Antiviral activity against multidrug-resistant HIV1 with reverse transcriptase 41L, 74V, 184V, 210W, 215Y, ins SS, 98G mutation infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA Antiviral activity against multidrug-resistant HIV1 with reverse transcriptase 41L, 74V, 184V, 210W, 215Y, ins SS, 98G mutation infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	[PMID: 19053755]
MT2	EC₅₀	>14.8 μM Compound: nevirapine	Antiviral activity against multidrug-resistant HIV1 with reverse transcriptase clone 7324-1 infected human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA Antiviral activity against multidrug-resistant HIV1 with reverse transcriptase clone 7324-1 infected human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	[PMID: 19053755]
MT2	EC₅₀	0.29 μM Compound: nevirapine	Antiviral activity against wild type HIV1 3B in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA Antiviral activity against wild type HIV1 3B in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	[PMID: 19053755]
MT2	CC₅₀	>100 μM Compound: Nevirapine	Cytotoxicity against human MT2 cells by MTT assay Cytotoxicity against human MT2 cells by MTT assay	[PMID: 20304641]
MT2	CC₅₀	>100 μM Compound: Nevirapine	Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase K103N/Y181C mutation by MTT assay Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase K103N/Y181C mutation by MTT assay	[PMID: 20304641]
MT2	CC₅₀	>100 μM Compound: Nevirapine	Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase Y181C mutation by MTT assay Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase Y181C mutation by MTT assay	[PMID: 20304641]
MT2	EC₅₀	0.11 μM Compound: Nevirapine	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of virus replication by MTT assay Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of virus replication by MTT assay	[PMID: 20304641]
MT2	EC₅₀	>3.7 μM Compound: 1	Antiviral activity against HIV1 with reverse transcriptase 6005MR mutant infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA Antiviral activity against HIV1 with reverse transcriptase 6005MR mutant infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	[PMID: 20527972]
MT2	EC₅₀	>3.7 μM Compound: 1	Antiviral activity against HIV1 with reverse transcriptase 8605MR mutant infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA Antiviral activity against HIV1 with reverse transcriptase 8605MR mutant infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	[PMID: 20527972]
MT2	EC₅₀	>3.7 μM Compound: 1	Antiviral activity against HIV1 with reverse transcriptase A17 (K103N, Y181C) mutant infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA Antiviral activity against HIV1 with reverse transcriptase A17 (K103N, Y181C) mutant infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	[PMID: 20527972]
MT2	EC₅₀	>3.7 μM Compound: 1	Antiviral activity against HIV1 with reverse transcriptase Y181C mutant infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA Antiviral activity against HIV1 with reverse transcriptase Y181C mutant infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	[PMID: 20527972]
MT2	EC₅₀	0.053 μM Compound: 1	Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	[PMID: 20527972]
MT2	IC₅₀	>266.3 ng/mL Compound: NEV	Inhibition of Human T-cell leukemia/lymphoma virus type 1 reverse transcriptase activity infected in human MT2 cells assessed as level of p19 antigen Inhibition of Human T-cell leukemia/lymphoma virus type 1 reverse transcriptase activity infected in human MT2 cells assessed as level of p19 antigen	[PMID: 21334901]
MT2	CC₅₀	>100 μM Compound: Nevirapine	Cytotoxicity against human MT2 cells infected with HIV1 NL4.3 by MTT assay Cytotoxicity against human MT2 cells infected with HIV1 NL4.3 by MTT assay	[PMID: 22081993]
MT2	EC₅₀	>100 μM Compound: Nevirapine	Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase K103N and Y181C double mutant infected in human MT2 cells assessed as inhibition of viral infection Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase K103N and Y181C double mutant infected in human MT2 cells assessed as inhibition of viral infection	[PMID: 22081993]
MT2	EC₅₀	>100 μM Compound: Nevirapine	Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase Y181C mutant infected in human MT2 cells assessed as inhibition of viral infection Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase Y181C mutant infected in human MT2 cells assessed as inhibition of viral infection	[PMID: 22081993]
MT2	EC₅₀	0.11 μM Compound: Nevirapine	Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT2 cells assessed as inhibition of viral infection Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT2 cells assessed as inhibition of viral infection	[PMID: 22081993]
MT2	CC₅₀	>100 μM Compound: Nevirapine	Cytotoxicity against human MT2 cells by MTT assay Cytotoxicity against human MT2 cells by MTT assay	[PMID: 22269110]
MT2	CC₅₀	>100 μM Compound: Nevirapine	Cytotoxicity in human MT2 cells assessed as inhibition of cell growth Cytotoxicity in human MT2 cells assessed as inhibition of cell growth	[PMID: 23298809]
MT2	EC₅₀	0.11 μM Compound: Nevirapine	Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method	[PMID: 23298809]
MT2	CC₅₀	>100 μM Compound: Nevirapine	Cytotoxicity against human MT2 cells by MTT assay Cytotoxicity against human MT2 cells by MTT assay	[PMID: 23899617]
MT2	EC₅₀	0.11 μM Compound: Nevirapine	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity by MTT assay	[PMID: 23899617]
MT2	CC₅₀	>100 μM Compound: Nevirapine	Cytotoxicity against human MT2 cells assessed as growth inhibition Cytotoxicity against human MT2 cells assessed as growth inhibition	[PMID: 23937980]
MT2	EC₅₀	0.11 μM Compound: Nevirapine	Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay	[PMID: 23937980]
MT2	CC₅₀	320 μM Compound: Nevirapine	Cytotoxicity against human MT2 cells after 4 to 5 days by MTT assay Cytotoxicity against human MT2 cells after 4 to 5 days by MTT assay	[PMID: 25176328]
MT2	EC₅₀	0.25 μM Compound: Nevirapine	Antiviral activity against X4 tropic HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTT assay Antiviral activity against X4 tropic HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTT assay	[PMID: 25176328]
MT2	CC₅₀	>100 μM Compound: nev	Cytotoxicity against human MT2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT2 cells assessed as reduction in cell viability by MTT assay	[PMID: 25408842]
MT2	EC₅₀	0.11 μM Compound: nev	Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay	[PMID: 25408842]
MT2	CC₅₀	>100 μM Compound: Nevirapine	Cytotoxicity against human MT2 cells assessed as growth inhibition by MTT method Cytotoxicity against human MT2 cells assessed as growth inhibition by MTT method	[PMID: 27485603]
MT2	CC₅₀	>100 μM Compound: Nevirapine	Cytotoxicity against human MT2 cells infected with wild-type HIV1 NL4-3 measured 48 hrs by MTT assay Cytotoxicity against human MT2 cells infected with wild-type HIV1 NL4-3 measured 48 hrs by MTT assay	[PMID: 31281023]
MT2	CC₅₀	96171 nM Compound: NVP	Cytotoxicity against human MT2 cells assessed as reduction in cell viability measured after 4 days by Trypan blue assay Cytotoxicity against human MT2 cells assessed as reduction in cell viability measured after 4 days by Trypan blue assay	[PMID: 31893549]
MT2	CC₅₀	>100 μM Compound: Nevirapine	Cytotoxicity against human MT2 cells assessed as cell growth inhibition after 5 days by MTT assay Cytotoxicity against human MT2 cells assessed as cell growth inhibition after 5 days by MTT assay	[PMID: 33603971]
MT2	EC₅₀	>100 μM Compound: Nevirapine	Cytotoxicity against human MT2 cells assessed as cell viability by MTT assay Cytotoxicity against human MT2 cells assessed as cell viability by MTT assay	[PMID: 35175760]
MT2	CC₅₀	>10 μM Compound: Nevirapine	Cytotoxic concentration against MT-2 cells Cytotoxic concentration against MT-2 cells	[PMID: 7684450]
MT2	IC₅₀	0.303 μM Compound: BI-RG-587	Inhibitory concentration which prevents the spread of HIV-1 IIIB infection in MT2 T-lymphoid cells Inhibitory concentration which prevents the spread of HIV-1 IIIB infection in MT2 T-lymphoid cells	[PMID: 7689109]
MT4	CC₅₀	>200 μM Compound: nevirapine	Cytotoxicity against mock-infected MT-4 cells. Cytotoxicity against mock-infected MT-4 cells.	[PMID: 10052969]
MT4	EC₅₀	0.25 μM Compound: nevirapine	Concentration required to achieve 50% protection of MT-4 cells from HIV-1-induced cytopathogenicity. Concentration required to achieve 50% protection of MT-4 cells from HIV-1-induced cytopathogenicity.	[PMID: 10052969]
MT4	ED₅₀	>5 μM Compound: Nevirapine	Inhibitory activity against HIV-1 Asn 103 mutant in MT-4 cells. Inhibitory activity against HIV-1 Asn 103 mutant in MT-4 cells.	[PMID: 10514285]
MT4	ED₅₀	>5 μM Compound: Nevirapine	Inhibitory activity against HIV-1 Cys 181 mutant in MT-4 cells. Inhibitory activity against HIV-1 Cys 181 mutant in MT-4 cells.	[PMID: 10514285]
MT4	ED₅₀	>5 μM Compound: Nevirapine	Inhibitory activity against HIV-1 Ile 100 mutant in MT-4 cells. Inhibitory activity against HIV-1 Ile 100 mutant in MT-4 cells.	[PMID: 10514285]
MT4	ED₅₀	>5 μM Compound: Nevirapine	Inhibitory activity against HIV-1 Wild Type in MT-4 cell culture (human T-cell line with 50% human AB serum) Inhibitory activity against HIV-1 Wild Type in MT-4 cell culture (human T-cell line with 50% human AB serum)	[PMID: 10514285]
MT4	ED₅₀	0.176 μM Compound: Nevirapine	Inhibition of wild type HIV-1 in MT-4 cell culture (human T cell line) Inhibition of wild type HIV-1 in MT-4 cell culture (human T cell line)	[PMID: 10514285]
MT4	EC₅₀	0.3 μM Compound: Nevirapine	Compound dose required to achieve protection of MT-4 cells from HIV-1 induced cytopathicity using MTT method Compound dose required to achieve protection of MT-4 cells from HIV-1 induced cytopathicity using MTT method	[PMID: 10698447]
MT4	CC₅₀	>200 μM Compound: Nevirapine	50% cytotoxic concentration against mock-infected MT-4 cells using MTT method 50% cytotoxic concentration against mock-infected MT-4 cells using MTT method	[PMID: 10794705]
MT4	EC₅₀	0.35 μM Compound: Nevirapine	Effective concentration against HIV-1 induced cytopathicity in MT-4 cells using MTT method Effective concentration against HIV-1 induced cytopathicity in MT-4 cells using MTT method	[PMID: 10794705]
MT4	IC₅₀	0.64 mM Compound: Nevirapine	50% inhibitory concentration against HIV-1 rRT in MT-4 cells 50% inhibitory concentration against HIV-1 rRT in MT-4 cells	[PMID: 10794705]
MT4	CC₅₀	>200 μM Compound: Nevirapine	Cytotoxicity against MT-4 cells. Cytotoxicity against MT-4 cells.	[PMID: 11472208]
MT4	EC₅₀	>30 μM Compound: Nevirapine	Anti-HIV-1 activity against Y181C HIV-1 strain in MT-4 cells Anti-HIV-1 activity against Y181C HIV-1 strain in MT-4 cells	[PMID: 11472208]
MT4	EC₅₀	0.3 μM Compound: Nevirapine	Effective concentration against HIV-1 induced cytopathogenicity in MT-4 cells Effective concentration against HIV-1 induced cytopathogenicity in MT-4 cells	[PMID: 11472208]
MT4	EC₅₀	0.37 μM Compound: Nevirapine	Anti-HIV-1 activity against WTIIIB HIV-1 strain in MT-4 cells Anti-HIV-1 activity against WTIIIB HIV-1 strain in MT-4 cells	[PMID: 11472208]
MT4	IC₅₀	>100 μM Compound: Nevirapine	Compound was tested for potency to achieve protection of MT-4 cells from 188L strain of HIV-1 virus Compound was tested for potency to achieve protection of MT-4 cells from 188L strain of HIV-1 virus	[PMID: 11527703]
MT4	IC₅₀	0.032 μM Compound: Nevirapine	Compound was tested for potency to achieve protection of MT-4 cells from LAI strain of HIV-1 virus Compound was tested for potency to achieve protection of MT-4 cells from LAI strain of HIV-1 virus	[PMID: 11527703]
MT4	IC₅₀	0.316 μM Compound: Nevirapine	Compound was tested for potency to achieve protection of MT-4 cells from 100I strain of HIV-1 virus Compound was tested for potency to achieve protection of MT-4 cells from 100I strain of HIV-1 virus	[PMID: 11527703]
MT4	IC₅₀	0.316 μM Compound: Nevirapine	Compound was tested for potency to achieve protection of MT-4 cells from 101E strain of HIV-1 virus Compound was tested for potency to achieve protection of MT-4 cells from 101E strain of HIV-1 virus	[PMID: 11527703]
MT4	IC₅₀	10 μM Compound: Nevirapine	Compound was tested for potency to achieve protection of MT-4 cells from 181C strain of HIV-1 virus Compound was tested for potency to achieve protection of MT-4 cells from 181C strain of HIV-1 virus	[PMID: 11527703]
MT4	IC₅₀	5.01 μM Compound: Nevirapine	Compound was tested for potency to achieve protection of MT-4 cells from 106A strain of HIV-1 virus Compound was tested for potency to achieve protection of MT-4 cells from 106A strain of HIV-1 virus	[PMID: 11527703]
MT4	IC₅₀	6.31 μM Compound: Nevirapine	Compound was tested for potency to achieve protection of MT-4 cells from 103N strain of HIV-1 virus Compound was tested for potency to achieve protection of MT-4 cells from 103N strain of HIV-1 virus	[PMID: 11527703]
MT4	IC₅₀	7.94 μM Compound: Nevirapine	Compound was tested for potency to achieve protection of MT-4 cells from 190A strain of HIV-1 virus Compound was tested for potency to achieve protection of MT-4 cells from 190A strain of HIV-1 virus	[PMID: 11527703]
MT4	IC₅₀	>100 μM Compound: Nevirapine	Inhibitory activity against 103N strain and 181C strain of HIV-I in MT-4 cells Inhibitory activity against 103N strain and 181C strain of HIV-I in MT-4 cells	[PMID: 11527705]
MT4	IC₅₀	>100 μM Compound: Nevirapine	Inhibitory activity against 188L strain of HIV-I in MT-4 cells Inhibitory activity against 188L strain of HIV-I in MT-4 cells	[PMID: 11527705]
MT4	IC₅₀	0.032 μM Compound: Nevirapine	Inhibitory activity against LAI strain of HIV-I in MT-4 cells Inhibitory activity against LAI strain of HIV-I in MT-4 cells	[PMID: 11527705]
MT4	IC₅₀	0.316 μM Compound: Nevirapine	Inhibitory activity against 100I strain of HIV-I in MT-4 cells Inhibitory activity against 100I strain of HIV-I in MT-4 cells	[PMID: 11527705]
MT4	IC₅₀	10 μM Compound: Nevirapine	Inhibitory activity against 181C strain of HIV-I in MT-4 cells Inhibitory activity against 181C strain of HIV-I in MT-4 cells	[PMID: 11527705]
MT4	IC₅₀	6.31 μM Compound: Nevirapine	Inhibitory activity against 103N strain of HIV-I in MT-4 cells Inhibitory activity against 103N strain of HIV-I in MT-4 cells	[PMID: 11527705]
MT4	IC₅₀	>10 μM Compound: Nevirapine	Anti-HIV-1 activity against K103N+Y181C strain was determined in MT-4 cells by the MTT method Anti-HIV-1 activity against K103N+Y181C strain was determined in MT-4 cells by the MTT method	[PMID: 14643315]
MT4	IC₅₀	>10 μM Compound: Nevirapine	Anti-HIV-1 activity against Y181C strain, in MT-4 cells by the MTT method Anti-HIV-1 activity against Y181C strain, in MT-4 cells by the MTT method	[PMID: 14643315]
MT4	IC₅₀	>10 μM Compound: Nevirapine	Anti-HIV-1 activity against Y188L strain was determined in MT-4 cells by the MTT method Anti-HIV-1 activity against Y188L strain was determined in MT-4 cells by the MTT method	[PMID: 14643315]
MT4	IC₅₀	>10 μM Compound: Nevirapine	Anti-HIV-1 activity against K103N+K1001 strain was determined Anti-HIV-1 activity against K103N+K1001 strain was determined	[PMID: 14643315]
MT4	IC₅₀	0.032 μM Compound: Nevirapine	Anti-HIV-1 activity against LAI strain in MT-4 cells by the MTT method Anti-HIV-1 activity against LAI strain in MT-4 cells by the MTT method	[PMID: 14643315]
MT4	IC₅₀	10 μM Compound: Nevirapine	Anti-HIV-1 activity against K1001 strain was determined in MT-4 cells by the MTT method Anti-HIV-1 activity against K1001 strain was determined in MT-4 cells by the MTT method	[PMID: 14643315]
MT4	IC₅₀	6.3 μM Compound: Nevirapine	Anti-HIV-1 activity against K103N strain in MT-4 cells by the MTT method Anti-HIV-1 activity against K103N strain in MT-4 cells by the MTT method	[PMID: 14643315]
MT4	EC₅₀	>30 μM Compound: Nevirapine	Effective dose required to achieve protection of MT-4 cells from Y181C HIV-1 induced cytopathogenicity Effective dose required to achieve protection of MT-4 cells from Y181C HIV-1 induced cytopathogenicity	[PMID: 14761194]
MT4	EC₅₀	0.37 μM Compound: Nevirapine	Effective dose required to achieve protection of MT-4 cells from wild type IIIB HIV-1 induced cytopathogenicity Effective dose required to achieve protection of MT-4 cells from wild type IIIB HIV-1 induced cytopathogenicity	[PMID: 14761194]
MT4	CC₅₀	>20 μg/mL Compound: BI-RG-587	Concentration required to reduce human MT-4 cell viability by 50%. Concentration required to reduce human MT-4 cell viability by 50%.	[PMID: 1495006]
MT4	IC₅₀	17200 nM Compound: Nevirapine	Antiviral activity against MT-4 cells infected with Nev-R strain of HIV-1 Antiviral activity against MT-4 cells infected with Nev-R strain of HIV-1	[PMID: 14971897]
MT4	IC₅₀	96 nM Compound: Nevirapine	Antiviral activity against MT-4 cells infected with wild-type HIV-1 Antiviral activity against MT-4 cells infected with wild-type HIV-1	[PMID: 14971897]
MT4	CC₅₀	>80 μM Compound: BI-RG-587	Cytotoxic concentration required to reduce MT-4 cell viability by 50% Cytotoxic concentration required to reduce MT-4 cell viability by 50%	[PMID: 1501224]
MT4	EC₅₀	0.128 μM Compound: BI-RG-587	Concentration required to inhibit HIV-1 induced cytopathicity in MT-4 cells by 50% Concentration required to inhibit HIV-1 induced cytopathicity in MT-4 cells by 50%	[PMID: 1501224]
MT4	IC₅₀	0.6 μM Compound: Nevirapine	Potency against non nucleoside reverse transcriptor was determined in MT-4 cells Potency against non nucleoside reverse transcriptor was determined in MT-4 cells	[PMID: 15109677]
MT4	CC₅₀	>200 μM Compound: Nevirapine	Cytotoxic concentration that reduces the MT-4 cell viability by 50% Cytotoxic concentration that reduces the MT-4 cell viability by 50%	[PMID: 15149669]
MT4	IC₅₀	0.25 μM Compound: Nevirapine	Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells	[PMID: 15149669]
MT4	CC₅₀	>100 μM Compound: NVP (Viramune)	In vitro cytotoxicity against mock infected MT-4 cells. In vitro cytotoxicity against mock infected MT-4 cells.	[PMID: 15239667]
MT4	EC₅₀	>30 μM Compound: NVP (Viramune)	Inhibition of Efavirenz resistant HIV-1 (K103N-Y181C) induced cytopathicity in MT-4 cells. Inhibition of Efavirenz resistant HIV-1 (K103N-Y181C) induced cytopathicity in MT-4 cells.	[PMID: 15239667]
MT4	EC₅₀	>30 μM Compound: NVP (Viramune)	Inhibition of Efavirenz resistant HIV-1 (Y181C) induced cytopathicity in MT-4 cells. Inhibition of Efavirenz resistant HIV-1 (Y181C) induced cytopathicity in MT-4 cells.	[PMID: 15239667]
MT4	EC₅₀	0.4 μM Compound: NVP (Viramune)	Inhibition of HIV-1 (IIIB) induced cytopathicity in MT-4 cells. Inhibition of HIV-1 (IIIB) induced cytopathicity in MT-4 cells.	[PMID: 15239667]
MT4	EC₅₀	>30 μM Compound: Nevirapine	Compound concentration required to achieve 50% protection of infected MT-4 cells from K103N-Y181C strain was determined by the MTT method Compound concentration required to achieve 50% protection of infected MT-4 cells from K103N-Y181C strain was determined by the MTT method	[PMID: 15634015]
MT4	EC₅₀	>30 μM Compound: Nevirapine	Compound concentration required to achieve 50% protection of infected MT-4 cells from Y181C strain was determined by the MTT method Compound concentration required to achieve 50% protection of infected MT-4 cells from Y181C strain was determined by the MTT method	[PMID: 15634015]
MT4	EC₅₀	>30 μM Compound: 1	Concentration required to achieve 50% protection of infected MT-4 cells from K103N-Y181C Concentration required to achieve 50% protection of infected MT-4 cells from K103N-Y181C	[PMID: 15634015]
MT4	EC₅₀	>30 μM Compound: 1	Concentration required to achieve 50% protection of infected MT-4 cells from Y181C-HIV-1 strain Concentration required to achieve 50% protection of infected MT-4 cells from Y181C-HIV-1 strain	[PMID: 15634015]
MT4	EC₅₀	0.37 μM Compound: Nevirapine	Concentration required for 50% protection of infected MT-4 cells from wtIIIB-HIV-1-induced cytopathogenicity was determined by the MTT method Concentration required for 50% protection of infected MT-4 cells from wtIIIB-HIV-1-induced cytopathogenicity was determined by the MTT method	[PMID: 15634015]
MT4	EC₅₀	0.37 μM Compound: 1	Protection of infected MT-4 cells from wtIIIB-HIV-1-induced cytopathogenicity Protection of infected MT-4 cells from wtIIIB-HIV-1-induced cytopathogenicity	[PMID: 15634015]
MT4	EC₅₀	>10 μM Compound: Nevirapine	Effective concentration of the compound to inhibit HIV-1 mutant K103N+Y181C replication in HIV-infected MT-4 cells Effective concentration of the compound to inhibit HIV-1 mutant K103N+Y181C replication in HIV-infected MT-4 cells	[PMID: 15771411]
MT4	EC₅₀	>100 μM Compound: Nevirapine	Effective concentration of the compound to inhibit HIV-1 mutant Y188L replication in HIV-infected MT-4 cells Effective concentration of the compound to inhibit HIV-1 mutant Y188L replication in HIV-infected MT-4 cells	[PMID: 15771411]
MT4	EC₅₀	0.032 μM Compound: Nevirapine	Effective concentration of the compound to inhibit HIV-1 mutant LAI replication in HIV-infected MT-4 cells Effective concentration of the compound to inhibit HIV-1 mutant LAI replication in HIV-infected MT-4 cells	[PMID: 15771411]
MT4	EC₅₀	0.32 μM Compound: Nevirapine	Effective concentration of the compound to inhibit HIV-1 mutant L100I replication in HIV-infected MT-4 cells Effective concentration of the compound to inhibit HIV-1 mutant L100I replication in HIV-infected MT-4 cells	[PMID: 15771411]
MT4	EC₅₀	10 μM Compound: Nevirapine	Effective concentration of the compound to inhibit HIV-1 mutant Y181C replication in HIV-infected MT-4 cells Effective concentration of the compound to inhibit HIV-1 mutant Y181C replication in HIV-infected MT-4 cells	[PMID: 15771411]
MT4	EC₅₀	6.31 μM Compound: Nevirapine	Effective concentration of the compound to inhibit HIV-1 mutant K103N replication in HIV-infected MT-4 cells Effective concentration of the compound to inhibit HIV-1 mutant K103N replication in HIV-infected MT-4 cells	[PMID: 15771411]
MT4	CC₅₀	>7.5 μM Compound: NVP	Cytotoxicity against MT4 cells by MTT method Cytotoxicity against MT4 cells by MTT method	[PMID: 16335924]
MT4	EC₅₀	>7.5 μM Compound: NVP	Antiviral activity against HIV1 IRLL98 mutant strain infected MT4 cells by MTT method Antiviral activity against HIV1 IRLL98 mutant strain infected MT4 cells by MTT method	[PMID: 16335924]
MT4	EC₅₀	>7.5 μM Compound: NVP	Antiviral activity against HIV1 Y188L mutant strain infected MT4 cells by MTT method Antiviral activity against HIV1 Y188L mutant strain infected MT4 cells by MTT method	[PMID: 16335924]
MT4	EC₅₀	0.052 μM Compound: NVP	Antiviral activity against wild type HIV1 NL4-3 infected MT4 cells by MTT method Antiviral activity against wild type HIV1 NL4-3 infected MT4 cells by MTT method	[PMID: 16335924]
MT4	EC₅₀	3.9 μM Compound: NVP	Antiviral activity against HIV1 K103N mutant strain infected MT4 cells by MTT method Antiviral activity against HIV1 K103N mutant strain infected MT4 cells by MTT method	[PMID: 16335924]
MT4	CC₅₀	>7.5 μM Compound: Nevirapine	Cytotoxicity against MT4 cells by MTT assay Cytotoxicity against MT4 cells by MTT assay	[PMID: 16621553]
MT4	EC₅₀	>7.5 μM Compound: Nevirapine	Antiviral activity against HIV1 IRLL98 in MT4 cells by MTT assay Antiviral activity against HIV1 IRLL98 in MT4 cells by MTT assay	[PMID: 16621553]
MT4	EC₅₀	>7.5 μM Compound: Nevirapine	Antiviral activity against HIV1 Y188L mutant in MT4 cells by MTT assay Antiviral activity against HIV1 Y188L mutant in MT4 cells by MTT assay	[PMID: 16621553]
MT4	EC₅₀	0.052 μM Compound: Nevirapine	Antiviral activity against wild type HIV1 NL4-3 in MT4 cells by MTT assay Antiviral activity against wild type HIV1 NL4-3 in MT4 cells by MTT assay	[PMID: 16621553]
MT4	EC₅₀	3.9 μM Compound: Nevirapine	Antiviral activity against HIV1 K103N mutant in MT4 cells by MTT assay Antiviral activity against HIV1 K103N mutant in MT4 cells by MTT assay	[PMID: 16621553]
MT4	EC₅₀	0.37 μM Compound: NVP	Antiviral activity against HIV1 3B in MT4 cell line Antiviral activity against HIV1 3B in MT4 cell line	[PMID: 16722636]
MT4	IC₅₀	12 μM Compound: NVP	Inhibition of reverse transcriptase activity in HIV1 NL4-3 infected MT4 cells after dialysis Inhibition of reverse transcriptase activity in HIV1 NL4-3 infected MT4 cells after dialysis	[PMID: 17116672]
MT4	IC₅₀	2 μM Compound: NVP	Inhibition of reverse transcriptase activity in HIV1 NL4-3 infected MT4 cells before dialysis Inhibition of reverse transcriptase activity in HIV1 NL4-3 infected MT4 cells before dialysis	[PMID: 17116672]
MT4	CC₅₀	31631 nM Compound: 14, nevirapine	Cytotoxicity against human MT4 cells after 3 days by EGFP based replication assay Cytotoxicity against human MT4 cells after 3 days by EGFP based replication assay	[PMID: 17223230]
MT4	EC₅₀	14505 nM Compound: 14, nevirapine	Antiviral activity against HIV1 LAI with RT K103N and Y181C mutation in MT4 cells by EGFP based replication assay Antiviral activity against HIV1 LAI with RT K103N and Y181C mutation in MT4 cells by EGFP based replication assay	[PMID: 17223230]
MT4	EC₅₀	1980 nM Compound: 14, nevirapine	Antiviral activity against HIV1 LAI with RT K103N mutation in MT4 cells by EGFP based replication assay Antiviral activity against HIV1 LAI with RT K103N mutation in MT4 cells by EGFP based replication assay	[PMID: 17223230]
MT4	EC₅₀	209 nM Compound: 14, nevirapine	Antiviral activity against HIV1 LAI with RT L100I mutation in MT4 cells by EGFP based replication assay Antiviral activity against HIV1 LAI with RT L100I mutation in MT4 cells by EGFP based replication assay	[PMID: 17223230]
MT4	EC₅₀	2697 nM Compound: 14, nevirapine	Antiviral activity against HIV1 LAI with RT F227C and V106A mutation in MT4 cells by EGFP based replication assay Antiviral activity against HIV1 LAI with RT F227C and V106A mutation in MT4 cells by EGFP based replication assay	[PMID: 17223230]
MT4	EC₅₀	33.3 nM Compound: 14, nevirapine	Antiviral activity against wild type HIV1 LAI infected in MT4 cells by EGFP based replication assay Antiviral activity against wild type HIV1 LAI infected in MT4 cells by EGFP based replication assay	[PMID: 17223230]
MT4	EC₅₀	3532 nM Compound: 14, nevirapine	Antiviral activity against HIV1 LAI with RT L100I and K103N mutation in MT4 cells by EGFP based replication assay Antiviral activity against HIV1 LAI with RT L100I and K103N mutation in MT4 cells by EGFP based replication assay	[PMID: 17223230]
MT4	EC₅₀	5910 nM Compound: 14, nevirapine	Antiviral activity against HIV1 LAI with RT Y188L mutation in MT4 cells by EGFP based replication assay Antiviral activity against HIV1 LAI with RT Y188L mutation in MT4 cells by EGFP based replication assay	[PMID: 17223230]
MT4	EC₅₀	7078 nM Compound: 14, nevirapine	Antiviral activity against HIV1 LAI with RT Y181C mutation in MT4 cells by EGFP based replication assay Antiviral activity against HIV1 LAI with RT Y181C mutation in MT4 cells by EGFP based replication assay	[PMID: 17223230]
MT4	EC₅₀	827 nM Compound: 14, nevirapine	Antiviral activity against HIV1 LAI with RT F227C mutation in MT4 cells by EGFP based replication assay Antiviral activity against HIV1 LAI with RT F227C mutation in MT4 cells by EGFP based replication assay	[PMID: 17223230]
MT4	CC₅₀	>15 μM Compound: nevirapine	Cytotoxicity against MT4 cells assessed as reduction of cell viability Cytotoxicity against MT4 cells assessed as reduction of cell viability	[PMID: 17276064]
MT4	EC₅₀	0.073 μM Compound: nevirapine	Antiviral activity against HIV1 assessed as reduction of virus-induced cytopathic effect in MT4 cells Antiviral activity against HIV1 assessed as reduction of virus-induced cytopathic effect in MT4 cells	[PMID: 17276064]
MT4	CC₅₀	>200 μM Compound: nevirapine	Cytotoxicity against MT4 cells after 4 days by MTT method Cytotoxicity against MT4 cells after 4 days by MTT method	[PMID: 17381078]
MT4	IC₅₀	0.25 μM Compound: nevirapine	Antiviral activity against wild type HIV1 3B in MT4 cells after 4 days by MTT method Antiviral activity against wild type HIV1 3B in MT4 cells after 4 days by MTT method	[PMID: 17381078]
MT4	CC₅₀	15 μM Compound: nevirapine	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 17803290]
MT4	EC₅₀	0.053 μM Compound: nevirapine	Antiviral activity against HIV1 3B in human MT4 cells by XTT assay Antiviral activity against HIV1 3B in human MT4 cells by XTT assay	[PMID: 17803290]
MT4	ED₅₀	>20000 nM Compound: NVP	Antiviral activity against HIV1 RT K103N-Y181C mutant in MT4 cells by MTT assay Antiviral activity against HIV1 RT K103N-Y181C mutant in MT4 cells by MTT assay	[PMID: 17803291]
MT4	ED₅₀	14000 nM Compound: NVP	Antiviral activity against HIV1 RT Y181C mutant in MT4 cells by MTT assay Antiviral activity against HIV1 RT Y181C mutant in MT4 cells by MTT assay	[PMID: 17803291]
MT4	ED₅₀	50 nM Compound: NVP	Antiviral activity against HIV1 3B in MT4 cells by MTT assay Antiviral activity against HIV1 3B in MT4 cells by MTT assay	[PMID: 17803291]
MT4	CC₅₀	>200 μM Compound: nevirapine	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 17869386]
MT4	IC₅₀	0.25 μM Compound: nevirapine	Antiviral activity against HIV 3B in human MT4 cells assessed as inhibition of viral replication by MTT assay Antiviral activity against HIV 3B in human MT4 cells assessed as inhibition of viral replication by MTT assay	[PMID: 17869386]
MT4	CC₅₀	>7 μM Compound: NVP, nevirapine	Cytotoxicity against MT4 cells after 4 days by MTT method Cytotoxicity against MT4 cells after 4 days by MTT method	[PMID: 17910429]
MT4	EC₅₀	0.08 μM Compound: NVP, nevirapine	Antiviral activity against HIV1 NL43 in MT4 cells assessed as inhibition of viral induced cytopathic effect after 4 days by MTT method Antiviral activity against HIV1 NL43 in MT4 cells assessed as inhibition of viral induced cytopathic effect after 4 days by MTT method	[PMID: 17910429]
MT4	EC₅₀	0.87 μM Compound: NVP, nevirapine	Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method	[PMID: 17910429]
MT4	EC₅₀	1.8 μM Compound: NVP, nevirapine	Antiviral activity against HIV1 with reverse transcriptase K103N mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method Antiviral activity against HIV1 with reverse transcriptase K103N mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method	[PMID: 17910429]
MT4	EC₅₀	5.6 μM Compound: NVP, nevirapine	Antiviral activity against HIV1 with reverse transcriptase Y188L mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method Antiviral activity against HIV1 with reverse transcriptase Y188L mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method	[PMID: 17910429]
MT4	EC₅₀	9.9 μM Compound: NVP, nevirapine	Antiviral activity against HIV1 with reverse transcriptase IRLL98 mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method Antiviral activity against HIV1 with reverse transcriptase IRLL98 mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method	[PMID: 17910429]
MT4	CC₅₀	683 μM Compound: nevirapine	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 17964796]
MT4	EC₅₀	0.03 μM Compound: nevirapine	Antiviral activity against HIV1 3B assessed as inhibition of virus-induced cytopathogenicity in MT4 cells after 4 days by MTT assay Antiviral activity against HIV1 3B assessed as inhibition of virus-induced cytopathogenicity in MT4 cells after 4 days by MTT assay	[PMID: 17964796]
MT4	CC₅₀	15 μM Compound: Nevirapine	Cytotoxicity against mock-infected human MT4 cells by MTT assay Cytotoxicity against mock-infected human MT4 cells by MTT assay	[PMID: 18083556]
MT4	EC₅₀	0.053 μM Compound: Nevirapine	Antiviral activity against HIV13B infected in human MT4 cells Antiviral activity against HIV13B infected in human MT4 cells	[PMID: 18083556]
MT4	CC₅₀	15 μM Compound: nevirapine	Cytotoxicity against human MT4 cells Cytotoxicity against human MT4 cells	[PMID: 18222088]
MT4	EC₅₀	0.053 μM Compound: nevirapine	Antiviral activity against HIV1 3B in MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV1 3B in MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18222088]
MT4	CC₅₀	>50 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 18242784]
MT4	EC₅₀	0.05 μM Compound: Nevirapine	Antiviral activity against HIV1 3B replication in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by tetrazolium-based colorimetric assay Antiviral activity against HIV1 3B replication in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by tetrazolium-based colorimetric assay	[PMID: 18242784]
MT4	EC₅₀	0.11 μM Compound: Nevirapine	Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 20 passages selected in presence of compound Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 20 passages selected in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.15 μM Compound: Nevirapine	Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 40 passages selected in presence of compound Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 40 passages selected in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.15 μM Compound: Nevirapine	Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 60 passages selected in presence of compound Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 60 passages selected in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.17 μM Compound: Nevirapine	Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18378713]
MT4	EC₅₀	0.31 μM Compound: Nevirapine	Antiviral activity against HIV 1 3B harboring integrase E92Q, S230N and L34M triple mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 60 passages in presence of compound Antiviral activity against HIV 1 3B harboring integrase E92Q, S230N and L34M triple mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 60 passages in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.35 μM Compound: Nevirapine	Antiviral activity against HIV 1 3B harboring integrase L34M mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 40 passages in presence of compound Antiviral activity against HIV 1 3B harboring integrase L34M mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 40 passages in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.38 μM Compound: Nevirapine	Antiviral activity against HIV 1 3B harboring integrase E92Q S230N double mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 20 passages in presence of compound Antiviral activity against HIV 1 3B harboring integrase E92Q S230N double mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 20 passages in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.46 μM Compound: Nevirapine	Antiviral activity against HIV 1 3B infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV 1 3B infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18378713]
MT4	CC₅₀	>15 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells Cytotoxicity against human MT4 cells	[PMID: 18585918]
MT4	EC₅₀	0.073 μM Compound: Nevirapine	Antiviral activity against HIV1 3B in human MT4 cells assessed as virus-induced cytopathogenicity after 5 days Antiviral activity against HIV1 3B in human MT4 cells assessed as virus-induced cytopathogenicity after 5 days	[PMID: 18585918]
MT4	CC₅₀	>7 μM Compound: NVP	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 18630898]
MT4	EC₅₀	>7 μM Compound: NVP	Antiviral activity against HIV1 isolates with reverse transcriptase Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 isolates with reverse transcriptase Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 18630898]
MT4	EC₅₀	>7 μM Compound: NVP	Antiviral activity against HIV1 isolates with reverse transcriptase Y188L mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 isolates with reverse transcriptase Y188L mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 18630898]
MT4	EC₅₀	0.13 μM Compound: NVP	Antiviral activity against HIV1 NL4-3 in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 NL4-3 in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 18630898]
MT4	EC₅₀	4.96 μM Compound: NVP	Antiviral activity against HIV1 isolates with reverse transcriptase K103N mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 isolates with reverse transcriptase K103N mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 18630898]
MT4	IC₅₀	10 nM Compound: Nevirapine	Antiviral activity against HIV1 infected in human MT4 cells Antiviral activity against HIV1 infected in human MT4 cells	[PMID: 18800765]
MT4	CC₅₀	>15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells Cytotoxicity against human MT4 cells	[PMID: 18824350]
MT4	EC₅₀	0.208 μM Compound: NVP	Antiviral activity against HIV1 3B in human MT4 cells assessed as protection of cell against virus-induced cytopathogenicity Antiviral activity against HIV1 3B in human MT4 cells assessed as protection of cell against virus-induced cytopathogenicity	[PMID: 18824350]
MT4	ED₅₀	>2 μM Compound: NVP	Antiviral activity against drug-resistant HIV1 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as virus-induced cell death by MTT method Antiviral activity against drug-resistant HIV1 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as virus-induced cell death by MTT method	[PMID: 18842407]
MT4	ED₅₀	0.04 μM Compound: NVP	Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as virus-induced cell death by MTT method Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as virus-induced cell death by MTT method	[PMID: 18842407]
MT4	ED₅₀	0.68 μM Compound: NVP	Antiviral activity against drug-resistant HIV1 with reverse transcriptase K103N mutant infected in human MT4 cells assessed as virus-induced cell death by MTT method Antiviral activity against drug-resistant HIV1 with reverse transcriptase K103N mutant infected in human MT4 cells assessed as virus-induced cell death by MTT method	[PMID: 18842407]
MT4	CC₅₀	>200 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 18952324]
MT4	EC₅₀	0.25 μM Compound: Nevirapine	Antiviral activity against HIV1 3B in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by MTT assay Antiviral activity against HIV1 3B in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by MTT assay	[PMID: 18952324]
MT4	CC₅₀	>4 μg/mL Compound: nevirapine	Cytotoxicity against mock-infected human MT4 cells by MTT assay Cytotoxicity against mock-infected human MT4 cells by MTT assay	[PMID: 19091580]
MT4	EC₅₀	>4 μg/mL Compound: nevirapine	Antiviral activity against HIV ROD in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV ROD in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 19091580]
MT4	EC₅₀	0.023 μg/mL Compound: nevirapine	Antiviral activity against HIV 3B in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV 3B in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	[PMID: 19091580]
MT4	CC₅₀	>7.5 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 19140683]
MT4	EC₅₀	>7.5 μM Compound: Nevirapine	Antiviral activity against HIV1 reverse transcriptase Y181C mutant infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 reverse transcriptase Y181C mutant infected in human MT4 cells after 5 days by MTT assay	[PMID: 19140683]
MT4	EC₅₀	>7.5 μM Compound: Nevirapine	Antiviral activity against HIV1 reverse transcriptase Y188L mutant infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 reverse transcriptase Y188L mutant infected in human MT4 cells after 5 days by MTT assay	[PMID: 19140683]
MT4	EC₅₀	0.08 μM Compound: Nevirapine	Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells after 5 days by MTT assay Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells after 5 days by MTT assay	[PMID: 19140683]
MT4	EC₅₀	3.9 μM Compound: Nevirapine	Antiviral activity against HIV1 reverse transcriptase K103N mutant infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 reverse transcriptase K103N mutant infected in human MT4 cells after 5 days by MTT assay	[PMID: 19140683]
MT4	CC₅₀	>15 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells after 5 days Cytotoxicity against human MT4 cells after 5 days	[PMID: 19616956]
MT4	EC₅₀	0.073 μM Compound: Nevirapine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days	[PMID: 19616956]
MT4	CC₅₀	>15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells as reduction in cell viability after 5 days by MTT assay	[PMID: 19628308]
MT4	EC₅₀	0.208 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus induced cytotoxicity after 5 days by MTT assay	[PMID: 19628308]
MT4	CC₅₀	>15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 19643613]
MT4	EC₅₀	0.208 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay	[PMID: 19643613]
MT4	IC₅₀	1 x 10⁴ nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring Y181C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring Y181C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	1 x 10⁵ nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring K103N and Y181C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring K103N and Y181C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	1 x 10⁵ nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring Y188L mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring Y188L mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	135 nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring 227C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 227C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	1452 nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring 100I and K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 100I and K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	163 nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring 227L and 106A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 227L and 106A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	195 nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring 179E mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 179E mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	31.6 nM Compound: NVP	Antiviral activity against HIV-1 LAI harboring wild type reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV-1 LAI harboring wild type reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	316 nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring 100I mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 100I mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	316 nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring 101E mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 101E mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	44 nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring 190S mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 190S mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	5012 nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring 106A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 106A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	509 nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring 101E and K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 101E and K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	51 nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring 138K mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 138K mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	6310 nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	IC₅₀	7943 nM Compound: NVP	Antiviral activity against HIV1 HXB2 harboring 190A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay Antiviral activity against HIV1 HXB2 harboring 190A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	[PMID: 19645483]
MT4	CC₅₀	>100 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction of cell viability after 4 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction of cell viability after 4 days by MTT assay	[PMID: 19775780]
MT4	EC₅₀	>20 μM Compound: NVP	Antiviral activity against HIV1 EFV with reverse transcriptase K103R, V179D, P225H mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 EFV with reverse transcriptase K103R, V179D, P225H mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 19775780]
MT4	EC₅₀	>20 μM Compound: NVP	Antiviral activity against NNRTI-resistant HIV1 A17 with reverse transcriptase K103N, Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against NNRTI-resistant HIV1 A17 with reverse transcriptase K103N, Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 19775780]
MT4	EC₅₀	0.3 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 19775780]
MT4	EC₅₀	7 μM Compound: NVP	Antiviral activity against NNRTI-resistant HIV1 N119 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against NNRTI-resistant HIV1 N119 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 19775780]
MT4	EC₅₀	<4.88 nM Compound: NVP	Antiviral activity against Human immunodeficiency virus 1 subtype C infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 subtype C infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	>31.25 μM Compound: NVP	Antiviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	14.4 nM Compound: NVP	Antiviral activity against Human immunodeficiency virus 1 subtype AG infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 subtype AG infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	14.88 nM Compound: NVP	Antiviral activity against Human immunodeficiency virus 1 subtype F1 infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 subtype F1 infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	24.17 nM Compound: NVP	Antiviral activity against Human immunodeficiency virus 1 subtype D infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 subtype D infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	24.63 nM Compound: NVP	Antiviral activity against Human immunodeficiency virus 1 subtype G infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 subtype G infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	25.99 nM Compound: NVP	Antiviral activity against Human immunodeficiency virus 1 subtype BG infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 subtype BG infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	34.09 nM Compound: NVP	Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	34.14 nM Compound: NVP	Antiviral activity against Human immunodeficiency virus 1 subtype (H) infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 subtype (H) infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	8.94 nM Compound: NVP	Antiviral activity against Human immunodeficiency virus 1 subtype AE infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 subtype AE infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	EC₅₀	9.32 nM Compound: NVP	Antiviral activity against Human immunodeficiency virus 1 subtype A1 infected in human MT4 cells assessed as reduction in virus induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 subtype A1 infected in human MT4 cells assessed as reduction in virus induced cytopathicity	[PMID: 19933797]
MT4	CC₅₀	>15 μM Compound: Nevirapine	Cytotoxicity in human MT4 cells assessed as reduction in cell viability Cytotoxicity in human MT4 cells assessed as reduction in cell viability	[PMID: 20097079]
MT4	EC₅₀	0.073 μM Compound: Nevirapine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed inhibition of viral-induced cytopathic effect after 5 days Antiviral activity against HIV1 3B infected in human MT4 cells assessed inhibition of viral-induced cytopathic effect after 5 days	[PMID: 20097079]
MT4	CC₅₀	>15.02 μM Compound: NEV	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 20307984]
MT4	EC₅₀	>15.02 μM Compound: NEV	Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20307984]
MT4	EC₅₀	0.2 μM Compound: NEV	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20307984]
MT4	CC₅₀	>15.02 μM Compound: NEV	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 20570527]
MT4	EC₅₀	>15.02 μM Compound: NEV	Antiviral activity against HIV1 bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV1 bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 20570527]
MT4	EC₅₀	0.075 μM Compound: NEV	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 20570527]
MT4	EC₅₀	>15037 nM Compound: NEV	Antiviral activity against HIV1 with reverse transcriptase F227L, V106A mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 with reverse transcriptase F227L, V106A mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20598556]
MT4	EC₅₀	>15037 nM Compound: NEV	Antiviral activity against HIV1 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20598556]
MT4	EC₅₀	>15037 nM Compound: NEV	Antiviral activity against HIV1 with reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 with reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20598556]
MT4	EC₅₀	102 nM Compound: NEV	Antiviral activity against wild type HIV1 LAI infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type HIV1 LAI infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20598556]
MT4	EC₅₀	1316 nM Compound: NEV	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20598556]
MT4	EC₅₀	162 nM Compound: NEV	Antiviral activity against HIV1 with reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 with reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20598556]
MT4	EC₅₀	2030 nM Compound: NEV	Antiviral activity against HIV1 with reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 with reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20598556]
MT4	EC₅₀	6729 nM Compound: NEV	Antiviral activity against HIV1 with reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 with reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20598556]
MT4	CC₅₀	≥15 μM Compound: NEV	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 20598556]
MT4	EC₅₀	≥15 μM Compound: NEV	Antiviral activity against HIV1 with reverse transcriptase K103N, Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against HIV1 with reverse transcriptase K103N, Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 20598556]
MT4	CC₅₀	683 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 20638854]
MT4	IC₅₀	0.03 μM Compound: Nevirapine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 20638854]
MT4	IC₅₀	15 μM Compound: Nevirapine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 20638854]
MT4	CC₅₀	156 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells after 5 days by spectrophotometry Cytotoxicity against human MT4 cells after 5 days by spectrophotometry	[PMID: 21093117]
MT4	EC₅₀	0.13 μM Compound: Nevirapine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by microtiter plate analysis Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by microtiter plate analysis	[PMID: 21093117]
MT4	CC₅₀	7510 nM Compound: NVP	Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay	[PMID: 21438533]
MT4	EC₅₀	>18850 nM Compound: NVP	Antiviral activity against multidrug-resistant HIV 1 IRLL98 harboring reverse transcriptase K101Q/Y181C/G190a mutant infected in human MT4 cells assessed as virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against multidrug-resistant HIV 1 IRLL98 harboring reverse transcriptase K101Q/Y181C/G190a mutant infected in human MT4 cells assessed as virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 21438533]
MT4	EC₅₀	>7510 nM Compound: NVP	Antiviral activity against HIV 1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV 1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 21438533]
MT4	EC₅₀	>7510 nM Compound: NVP	Antiviral activity against HIV 1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV 1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 21438533]
MT4	EC₅₀	131.4 nM Compound: NVP	Antiviral activity against wild type HIV 1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV 1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 21438533]
MT4	EC₅₀	6121 nM Compound: NVP	Antiviral activity against HIV 1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV 1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 21438533]
MT4	CC₅₀	>15.02 μM Compound: NVP	Cytotoxic activity against human MT4 cells assessed as viability of mock-infected cells after 5 days by MTT assay Cytotoxic activity against human MT4 cells assessed as viability of mock-infected cells after 5 days by MTT assay	[PMID: 21683601]
MT4	EC₅₀	0.21 μM Compound: NVP	Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 21683601]
MT4	CC₅₀	>15.02 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 21824782]
MT4	EC₅₀	>9.5 μM Compound: Nevirapine	Antiviral activity against wild type Human immunodeficiency virus 1 3B bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type Human immunodeficiency virus 1 3B bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 21824782]
MT4	EC₅₀	0.18 μM Compound: Nevirapine	Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 21824782]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	>15 μM Compound: NVP	Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	0.18 μM Compound: NVP	Antiviral activity against HIV-1 3B harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-1 3B harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	0.19 μM Compound: NVP	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	1.92 μM Compound: NVP	Antiviral activity against HIV-1 3B harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-1 3B harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	EC₅₀	7.25 μM Compound: NVP	Antiviral activity against HIV-1 3B harboring RT K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV-1 3B harboring RT K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 21872971]
MT4	CC₅₀	>15 μM Compound: Nevirapine, Viramune	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 21903401]
MT4	EC₅₀	>15 μM Compound: Nevirapine, Viramune	Antiviral activity against HIV1 3B expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 21903401]
MT4	EC₅₀	0.075 μM Compound: Nevirapine, Viramune	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 21903401]
MT4	CC₅₀	>15.02 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells measured by MTT assay Cytotoxicity against human MT4 cells measured by MTT assay	[PMID: 22037050]
MT4	EC₅₀	>15.02 μM Compound: Nevirapine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 22037050]
MT4	EC₅₀	0.21 μM Compound: Nevirapine	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 22037050]
MT4	EC₅₀	3.49 μM Compound: Nevirapine	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 22037050]
MT4	EC₅₀	>10 μM Compound: Nevirapine	Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase K103N and Y181C double mutant infected in human MT4 cells assessed as inhibition of viral infection Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase K103N and Y181C double mutant infected in human MT4 cells assessed as inhibition of viral infection	[PMID: 22081993]
MT4	EC₅₀	>10 μM Compound: Nevirapine	Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral infection Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral infection	[PMID: 22081993]
MT4	EC₅₀	0.081 μM Compound: Nevirapine	Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT4 cells assessed as inhibition of viral infection Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT4 cells assessed as inhibition of viral infection	[PMID: 22081993]
MT4	CC₅₀	325.13 μM Compound: NVP	Cytotoxicity against human MT4 cells after 3 days by XTT assay Cytotoxicity against human MT4 cells after 3 days by XTT assay	[PMID: 22283377]
MT4	EC₅₀	>10 μM Compound: NVP	Antiviral activity against NNRTI-resistant HIV1 A17 expressing reverse transcriptase K103N and Y181C mutant infected in human MT4 cells assessed as inhibition of viral p24 antigen production after 7 days by ELISA Antiviral activity against NNRTI-resistant HIV1 A17 expressing reverse transcriptase K103N and Y181C mutant infected in human MT4 cells assessed as inhibition of viral p24 antigen production after 7 days by ELISA	[PMID: 22283377]
MT4	EC₅₀	0.068 μM Compound: NVP	Antiviral activity against HIV1 SF33 infected in human MT4 cells assessed as inhibition of viral p24 antigen production after 7 days by ELISA Antiviral activity against HIV1 SF33 infected in human MT4 cells assessed as inhibition of viral p24 antigen production after 7 days by ELISA	[PMID: 22283377]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22405288]
MT4	EC₅₀	11.2 μM Compound: NVP	Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 22405288]
MT4	EC₅₀	90.1 nM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 22405288]
MT4	CC₅₀	7500 nM Compound: NVP	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22428851]
MT4	EC₅₀	>7500 nM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22428851]
MT4	EC₅₀	>7500 nM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22428851]
MT4	EC₅₀	130 nM Compound: NVP	Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22428851]
MT4	EC₅₀	6100 nM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22428851]
MT4	CC₅₀	>15 μM Compound: NEV	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22575532]
MT4	EC₅₀	>15 μM Compound: NEV	Antiviral activity against HIV2 ROD mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22575532]
MT4	EC₅₀	0.21 μM Compound: NEV	Antiviral activity against HIV1 3B harboring wild type RT infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B harboring wild type RT infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22575532]
MT4	EC₅₀	3.5 μM Compound: NEV	Antiviral activity against HIV1 RES056 harboring K103N/Y181C RT mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 harboring K103N/Y181C RT mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22575532]
MT4	CC₅₀	>15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22591854]
MT4	EC₅₀	>15.02 μM Compound: NVP	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22591854]
MT4	EC₅₀	200.4 nM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 22591854]
MT4	CC₅₀	>5 μg/mL Compound: NVP	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 22652226]
MT4	EC₅₀	0.11 μM Compound: NVP	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days	[PMID: 22652226]
MT4	CC₅₀	>18776 nM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells measured after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells measured after 5 days by MTT assay	[PMID: 22712652]
MT4	EC₅₀	>18916 nM Compound: NVP	Antiviral activity against HIV1 IRLL98 containing reverse transcriptase K101Q, Y181C and G190A mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV1 IRLL98 containing reverse transcriptase K101Q, Y181C and G190A mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 22712652]
MT4	EC₅₀	>3756 nM Compound: NVP	Antiviral activity against HIV1 containing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV1 containing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 22712652]
MT4	EC₅₀	>3756 nM Compound: NVP	Antiviral activity against HIV1 containing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV1 containing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 22712652]
MT4	EC₅₀	>3756 nM Compound: NVP	Antiviral activity against HIV1 containing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV1 containing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 22712652]
MT4	EC₅₀	1502 nM Compound: NVP	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	[PMID: 22712652]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells by MTT assay Cytotoxicity against mock-infected human MT4 cells by MTT assay	[PMID: 22883027]
MT4	EC₅₀	>15 μM Compound: NVP	Antiviral activity against HIV-1 RES056 harboring RT K103N/Y181C mutant gene infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay Antiviral activity against HIV-1 RES056 harboring RT K103N/Y181C mutant gene infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay	[PMID: 22883027]
MT4	EC₅₀	0.2 μM Compound: NVP	Antiviral activity against HIV-1 3B infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay Antiviral activity against HIV-1 3B infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay	[PMID: 22883027]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 23084898]
MT4	EC₅₀	0.09 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	[PMID: 23084898]
MT4	EC₅₀	11 μM Compound: NVP	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	[PMID: 23084898]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay	[PMID: 23098609]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against HIV2 ROD infected in human MT4 cells by MTT assay Cytotoxicity against HIV2 ROD infected in human MT4 cells by MTT assay	[PMID: 23098609]
MT4	EC₅₀	0.09 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 23098609]
MT4	CC₅₀	>14.99 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 23159806]
MT4	EC₅₀	0.097 μM Compound: NVP	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 23159806]
MT4	EC₅₀	≥7.6 μM Compound: NVP	Antiviral activity against HIV1 RES056 harbouring RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 harbouring RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 23159806]
MT4	CC₅₀	>4 μM Compound: NVP, Viramune	Cytotoxicity against human MT4 cells after 4 days by MTT assay Cytotoxicity against human MT4 cells after 4 days by MTT assay	[PMID: 23357038]
MT4	EC₅₀	0.048 μM Compound: NVP, Viramune	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	[PMID: 23357038]
MT4	CC₅₀	>14.9 μM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 23415090]
MT4	EC₅₀	0.199 μM Compound: NVP	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay	[PMID: 23415090]
MT4	CC₅₀	325.13 μM Compound: NVP	Cytotoxicity against human MT4 cells after 3 days by XTT assay Cytotoxicity against human MT4 cells after 3 days by XTT assay	[PMID: 23540737]
MT4	EC₅₀	>10 μM Compound: NVP	Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 A17 double mutant infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 A17 double mutant infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA	[PMID: 23540737]
MT4	EC₅₀	>10 μM Compound: NVP	Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 harboring reverse transcriptase K103N mutation infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 harboring reverse transcriptase K103N mutation infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA	[PMID: 23540737]
MT4	EC₅₀	>10 μM Compound: NVP	Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 harboring reverse transcriptase Y181C mutation infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 harboring reverse transcriptase Y181C mutation infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA	[PMID: 23540737]
MT4	EC₅₀	0.068 μM Compound: NVP	Antiviral activity against Human immunodeficiency virus 1 SF33 infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA Antiviral activity against Human immunodeficiency virus 1 SF33 infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA	[PMID: 23540737]
MT4	CC₅₀	>15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 23707918]
MT4	EC₅₀	>15.02 μM Compound: NVP	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 23707918]
MT4	EC₅₀	0.11 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 23707918]
MT4	EC₅₀	5.12 μM Compound: NVP	Antiviral activity against HIV1 RES056 expressing RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 23707918]
MT4	CC₅₀	15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 24055077]
MT4	EC₅₀	0.084 μM Compound: NVP	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24055077]
MT4	EC₅₀	1.97 μM Compound: NVP	Antiviral activity against HIV-1 RESO56 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV-1 RESO56 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24055077]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 24119448]
MT4	EC₅₀	0.11 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against viral-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against viral-induced cytotoxicity after 5 days by MTT assay	[PMID: 24119448]
MT4	CC₅₀	>15 μM Compound: NEV	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	[PMID: 24134904]
MT4	EC₅₀	>5 μM Compound: NEV	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24134904]
MT4	EC₅₀	0.113 μM Compound: NEV	Antiviral activity against wild-type HIV1 3B infected in MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild-type HIV1 3B infected in MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24134904]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 24239481]
MT4	EC₅₀	0.17 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT-4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT-4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay	[PMID: 24239481]
MT4	EC₅₀	2.5 μM Compound: NVP	Antiviral activity against drug-resistant HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT-4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay Antiviral activity against drug-resistant HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT-4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay	[PMID: 24239481]
MT4	CC₅₀	>15.02 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells assessed as cell viability Cytotoxicity against human MT4 cells assessed as cell viability	[PMID: 24457088]
MT4	EC₅₀	0.19 μM Compound: Nevirapine	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days	[PMID: 24457088]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 24581546]
MT4	EC₅₀	0.18 μM Compound: NVP	Antiviral activity against HIV1 3B harboring wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B harboring wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24581546]
MT4	EC₅₀	3.5 μM Compound: NVP	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 24581546]
MT4	CC₅₀	>15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as growth inhibition after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as growth inhibition after 5 days by MTT assay	[PMID: 24602795]
MT4	EC₅₀	0.23 μM Compound: NVP	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24602795]
MT4	EC₅₀	4.09 μM Compound: NVP	Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24602795]
MT4	CC₅₀	>14.99 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay	[PMID: 24631361]
MT4	EC₅₀	0.17 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay	[PMID: 24631361]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	[PMID: 24680058]
MT4	EC₅₀	0.101 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay	[PMID: 24680058]
MT4	EC₅₀	0.901 μM Compound: NVP	Antiviral activity against HIV1 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV1 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay	[PMID: 24680058]
MT4	CC₅₀	>18776 nM Compound: NVP	Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay	[PMID: 24769348]
MT4	EC₅₀	>3756 nM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	[PMID: 24769348]
MT4	EC₅₀	>3756 nM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	[PMID: 24769348]
MT4	EC₅₀	>3756 nM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	[PMID: 24769348]
MT4	EC₅₀	>3756 nM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	[PMID: 24769348]
MT4	EC₅₀	112.4 nM Compound: NVP	Antiviral activity against HIV1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method Antiviral activity against HIV1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	[PMID: 24769348]
MT4	EC₅₀	60 nM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase L1001 mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method Antiviral activity against HIV1 harboring reverse transcriptase L1001 mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	[PMID: 24769348]
MT4	CC₅₀	15 μM Compound: 1, NVP	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 24794751]
MT4	EC₅₀	>15 μM Compound: 1, NVP	Antiviral activity against HIV1 RES056 harboring RT K103N,Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay Antiviral activity against HIV1 RES056 harboring RT K103N,Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay	[PMID: 24794751]
MT4	EC₅₀	0.09 μM Compound: 1, NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay	[PMID: 24794751]
MT4	CC₅₀	>100 μM Compound: NVP	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	[PMID: 24805780]
MT4	EC₅₀	>10 μM Compound: NVP	Antiviral activity against A17-sensitive HIV1 harboring 103N, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against A17-sensitive HIV1 harboring 103N, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	>10 μM Compound: NVP	Antiviral activity against efavirenz-resistant HIV1 harboring RT 100I, 103R, 179D, 225H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against efavirenz-resistant HIV1 harboring RT 100I, 103R, 179D, 225H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	>10 μM Compound: NVP	Antiviral activity against N119-sensitive HIV1 harboring Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against N119-sensitive HIV1 harboring Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	>20 μM Compound: NVP	Antiviral activity against 6-[(3,5-Dimethylphenyl)fluoromethyl]-5-ethyl-1-{[[4-(3-hydroxyprop-1-ynyl)benzyl]oxy]methyl}pyrimidine-2,4(1H,3H)-dione-resistant HIV1 harboring RT 106I, 181C mutant infected in human MT4 cells assessed as inhibition of virus-in Antiviral activity against 6-[(3,5-Dimethylphenyl)fluoromethyl]-5-ethyl-1-{[[4-(3-hydroxyprop-1-ynyl)benzyl]oxy]methyl}pyrimidine-2,4(1H,3H)-dione-resistant HIV1 harboring RT 106I, 181C mutant infected in human MT4 cells assessed as inhibition of virus-in	[PMID: 24805780]
MT4	EC₅₀	>20 μM Compound: NVP	Antiviral activity against TMC125-resistant HIV1 harboring RT 109M, 138K, 190E mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against TMC125-resistant HIV1 harboring RT 109M, 138K, 190E mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.06 μM Compound: NVP	Antiviral activity against zidovudine-resistant HIV1 harboring RT 67N, 70R, 215F, 219Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against zidovudine-resistant HIV1 harboring RT 67N, 70R, 215F, 219Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.3 μM Compound: NVP	Antiviral activity against saquinavir-resistant HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against saquinavir-resistant HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	0.3 μM Compound: NVP	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	1 μM Compound: NVP	Antiviral activity against TMC120-resistant HIV1 harboring RT 100I, 138G mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against TMC120-resistant HIV1 harboring RT 100I, 138G mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	3 μM Compound: NVP	Antiviral activity against MDR-resistant HIV1 harboring 41L, 74V, 106A, 215Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against MDR-resistant HIV1 harboring 41L, 74V, 106A, 215Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	EC₅₀	4 μM Compound: NVP	Antiviral activity against MC1220-resistant HIV1 harboring RT 100I, 179D, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay Antiviral activity against MC1220-resistant HIV1 harboring RT 100I, 179D, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	[PMID: 24805780]
MT4	CC₅₀	>15 μM Compound: nevirapine	Cytotoxicity against human MT4 cells assessed as inhibition of overall cell metabolism after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as inhibition of overall cell metabolism after 5 days by MTT assay	[PMID: 24926807]
MT4	IC₅₀	>15 μM Compound: nevirapine	Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay	[PMID: 24926807]
MT4	IC₅₀	0.01 μM Compound: nevirapine	Antiviral activity against Human immunodeficiency virus 1 3b infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 3b infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay	[PMID: 24926807]
MT4	CC₅₀	>7 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as induction of cell death by MTT method Cytotoxicity against human MT4 cells assessed as induction of cell death by MTT method	[PMID: 24933420]
MT4	EC₅₀	>7 μM Compound: NVP	Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method	[PMID: 24933420]
MT4	EC₅₀	>7 μM Compound: NVP	Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method	[PMID: 24933420]
MT4	EC₅₀	0.12 μM Compound: NVP	Antiviral activity against wild type HIV-1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method Antiviral activity against wild type HIV-1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method	[PMID: 24933420]
MT4	EC₅₀	5.6 μM Compound: NVP	Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method	[PMID: 24933420]
MT4	CC₅₀	>15.021 μM Compound: NVP	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 24952305]
MT4	IC₅₀	0.101 μM Compound: NVP	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24952305]
MT4	IC₅₀	0.9 μM Compound: NVP	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 24952305]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	[PMID: 25089812]
MT4	EC₅₀	0.15 μM Compound: NVP	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as protection from viral cytopathicity after 5 days by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as protection from viral cytopathicity after 5 days by MTT assay	[PMID: 25089812]
MT4	EC₅₀	2.9 μM Compound: NVP	Antiviral activity against HIV-1 RES056 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as protection from viral cytopathicity after 5 days by MTT assay Antiviral activity against HIV-1 RES056 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as protection from viral cytopathicity after 5 days by MTT assay	[PMID: 25089812]
MT4	CC₅₀	>15 μM Compound: Nevirapine	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	[PMID: 25127466]
MT4	EC₅₀	>15 μM Compound: Nevirapine	Antiviral activity against HIV2 ROD acutely infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD acutely infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenic effect after 5 days by MTT assay	[PMID: 25127466]
MT4	EC₅₀	0.18 μM Compound: Nevirapine	Antiviral activity against HIV1 3B acutely infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenic effect after 5 days by MTT assay Antiviral activity against HIV1 3B acutely infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenic effect after 5 days by MTT assay	[PMID: 25127466]
MT4	CC₅₀	>14.4 μM Compound: NVP	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 25150090]
MT4	EC₅₀	>14.4 μM Compound: NVP	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay	[PMID: 25150090]
MT4	EC₅₀	0.18 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay	[PMID: 25150090]
MT4	CC₅₀	>15.02 μM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	[PMID: 25240095]
MT4	EC₅₀	>7.58 μM Compound: NVP	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 25240095]
MT4	EC₅₀	0.31 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	[PMID: 25240095]
MT4	CC₅₀	>18776 nM Compound: NVP	Cytotoxic activity against human MT4 cells by MTT assay Cytotoxic activity against human MT4 cells by MTT assay	[PMID: 25418038]
MT4	EC₅₀	>3756 nM Compound: NVP	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	[PMID: 25418038]
MT4	EC₅₀	>3756 nM Compound: NVP	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase K103N-Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase K103N-Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	[PMID: 25418038]
MT4	EC₅₀	>3756 nM Compound: NVP	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	[PMID: 25418038]
MT4	EC₅₀	>3756 nM Compound: NVP	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	[PMID: 25418038]
MT4	EC₅₀	112.4 nM Compound: NVP	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	[PMID: 25418038]
MT4	EC₅₀	60 nM Compound: NVP	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	[PMID: 25418038]
MT4	CC₅₀	>15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells after 5 days MTT assay Cytotoxicity against human MT4 cells after 5 days MTT assay	[PMID: 25537532]
MT4	EC₅₀	0.31 μM Compound: NVP	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25537532]
MT4	EC₅₀	≥7.59 μM Compound: NVP	Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25537532]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 25626145]
MT4	EC₅₀	312 nM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25626145]
MT4	EC₅₀	≥7.6 μM Compound: NVP	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25626145]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability Cytotoxicity against human MT4 cells assessed as reduction in cell viability	[PMID: 25638501]
MT4	EC₅₀	0.31 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenic effect Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenic effect	[PMID: 25638501]
MT4	EC₅₀	>4 μM Compound: Nevirapine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 25682562]
MT4	EC₅₀	0.027 μM Compound: Nevirapine	Antiviral activity against HIV1 3B infected infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B infected infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	[PMID: 25682562]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 25707013]
MT4	EC₅₀	0.31 μM Compound: NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25707013]
MT4	EC₅₀	≥7.6 μM Compound: NVP	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 25707013]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	[PMID: 25907370]
MT4	EC₅₀	0.244 μM Compound: NVP	Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay	[PMID: 25907370]
MT4	EC₅₀	≥11 μM Compound: NVP	Antiviral activity against HIV1 harboring K103N/Y181C double mutant infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay Antiviral activity against HIV1 harboring K103N/Y181C double mutant infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay	[PMID: 25907370]
MT4	CC₅₀	>15 μM Compound: nevirapine	Cytotoxicity against human MT4 cells assessed as inhibition of cell metabolism after 72 hrs by MTS assay Cytotoxicity against human MT4 cells assessed as inhibition of cell metabolism after 72 hrs by MTS assay	[PMID: 25946116]
MT4	EC₅₀	>15 μM Compound: nevirapine	Antiviral activity against HIV2-ROD infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay Antiviral activity against HIV2-ROD infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay	[PMID: 25946116]
MT4	EC₅₀	0.01 μM Compound: nevirapine	Antiviral activity against HIV1-3B infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay Antiviral activity against HIV1-3B infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay	[PMID: 25946116]
MT4	EC₅₀	0.1 μM Compound: Nevirapine	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 3 to 4 days by MTT assay Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 3 to 4 days by MTT assay	[PMID: 25970729]
MT4	EC₅₀	0.2 μM Compound: 1, BI-RG-587	Antiviral activity against wild-type HIV-1 infected in human MT4 cells Antiviral activity against wild-type HIV-1 infected in human MT4 cells	[PMID: 26276432]
MT4	CC₅₀	>15021 nM Compound: 1, NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay	[PMID: 26276435]
MT4	EC₅₀	312 nM Compound: 1, NVP	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity incubated for 4 days by MTT method Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity incubated for 4 days by MTT method	[PMID: 26276435]
MT4	EC₅₀	≥7585 nM Compound: 1, NVP	Antiviral activity against HIV1 3B expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity incubated for 4 days by MTT method Antiviral activity against HIV1 3B expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity incubated for 4 days by MTT method	[PMID: 26276435]
MT4	CC₅₀	>15.02 μM Compound: Nevirapine	Cytotoxicity against uninfected human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against uninfected human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 26385446]
MT4	EC₅₀	0.3117 μM Compound: Nevirapine	Antiviral activity against wild type HIV 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against wild type HIV 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 26385446]
MT4	EC₅₀	≥2.02 μg/mL Compound: Nevirapine	Antiviral activity against HIV 1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against HIV 1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 26385446]
MT4	CC₅₀	>15 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 26613134]
MT4	EC₅₀	>15 μM Compound: Nevirapine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26613134]
MT4	EC₅₀	>15 μM Compound: Nevirapine	Antiviral activity against nevirapine-resistant SIV mac251 infected in human MT4 cells Antiviral activity against nevirapine-resistant SIV mac251 infected in human MT4 cells	[PMID: 26613134]
MT4	EC₅₀	>15 μM Compound: Nevirapine	Antiviral activity against NNRTI-resistant HIV1 RES056 harboring reverse transcriptase K103N/181C double mutant infected in human MT4 cells Antiviral activity against NNRTI-resistant HIV1 RES056 harboring reverse transcriptase K103N/181C double mutant infected in human MT4 cells	[PMID: 26613134]
MT4	EC₅₀	>15 μM Compound: Nevirapine	Antiviral activity against NRTI/NNRTI-resistant HIV1 L6 harboring reverse transcriptase V75I/F77L/K103N/F116Y/Q151M/M184V mutant infected in human MT4 cells Antiviral activity against NRTI/NNRTI-resistant HIV1 L6 harboring reverse transcriptase V75I/F77L/K103N/F116Y/Q151M/M184V mutant infected in human MT4 cells	[PMID: 26613134]
MT4	EC₅₀	0.28 μM Compound: Nevirapine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26613134]
MT4	EC₅₀	0.23 μM Compound: NVP	Antiviral activity against HIV1 3B expressing reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.26 μM Compound: NVP	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	0.83 μM Compound: NVP	Antiviral activity against HIV1 3B expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	6.21 μM Compound: NVP	Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	6.78 μM Compound: NVP	Antiviral activity against HIV1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	7.17 μM Compound: NVP	Antiviral activity against HIV1 RES056 expressing reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	EC₅₀	9.61 μM Compound: NVP	Antiviral activity against HIV1 3B expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26802545]
MT4	CC₅₀	>15.02 μM Compound: NVP	Cytotoxicity against mock infected human MT4 cells after 4 days by MTT assay Cytotoxicity against mock infected human MT4 cells after 4 days by MTT assay	[PMID: 26994843]
MT4	EC₅₀	>15.02 μM Compound: NVP	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/YI81C double mutant infected in human MT4 cells assessed as cell viability after 4 days by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/YI81C double mutant infected in human MT4 cells assessed as cell viability after 4 days by MTT assay	[PMID: 26994843]
MT4	EC₅₀	0.28 μM Compound: NVP	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as cell viability after 4 days by MTT assay Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as cell viability after 4 days by MTT assay	[PMID: 26994843]
MT4	CC₅₀	4 μg/mL Compound: Nevirapine	Cytotoxicity against human MT4 cells infected with HIV1 3B assessed as cell growth inhibition after 5 days by MTT assay Cytotoxicity against human MT4 cells infected with HIV1 3B assessed as cell growth inhibition after 5 days by MTT assay	[PMID: 27105027]
MT4	IC₅₀	0.075 μg/mL Compound: Nevirapine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenic effect after 5 days by MTT assay	[PMID: 27105027]
MT4	CC₅₀	>18 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells after 5 days MTT assay Cytotoxicity against human MT4 cells after 5 days MTT assay	[PMID: 27112451]
MT4	EC₅₀	0.31 μM Compound: Nevirapine	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 27112451]
MT4	CC₅₀	>4 μg/mL Compound: Nevirapine	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 27214512]
MT4	EC₅₀	>4 μg/mL Compound: Nevirapine	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay	[PMID: 27214512]
MT4	EC₅₀	0.05 μg/mL Compound: Nevirapine	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay	[PMID: 27214512]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells Cytotoxicity against mock-infected human MT4 cells	[PMID: 27234889]
MT4	EC₅₀	0.11 μM Compound: NVP	Antiviral activity against HIV-1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV-1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 27234889]
MT4	EC₅₀	0.22 μM Compound: NVP	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 27234889]
MT4	EC₅₀	7.64 μM Compound: NVP	Antiviral activity against HIV-1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV-1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 27234889]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 27267005]
MT4	EC₅₀	0.29 μM Compound: NVP	Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 27267005]
MT4	EC₅₀	≥9.8 μM Compound: NVP	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 27267005]
MT4	CC₅₀	≥15.02 μM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells assessed as reduction of cell viability after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction of cell viability after 5 days by MTT assay	[PMID: 27501911]
MT4	CC₅₀	>15020 nM Compound: NVP	Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	>15021 nM Compound: NVP	Antiviral activity against HIV1 3B harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	>15021 nM Compound: NVP	Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	15021 nM Compound: NVP	Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	2107 nM Compound: NVP	Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	250 nM Compound: NVP	Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	271 nM Compound: NVP	Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	5392 nM Compound: NVP	Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	EC₅₀	≥7590 nM Compound: NVP	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	[PMID: 27541578]
MT4	CC₅₀	>4 μg/mL Compound: Nevirapine	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 27647368]
MT4	IC₅₀	>4 μg/mL Compound: Nevirapine	Antiviral activity against HIV-2 ROD infected in human MT-4 cells assessed as protection against virus induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV-2 ROD infected in human MT-4 cells assessed as protection against virus induced cytopathic effect after 5 days by MTT assay	[PMID: 27647368]
MT4	IC₅₀	0.05 μg/mL Compound: Nevirapine	Antiviral activity against HIV-1 3B infected in human MT-4 cells assessed as protection against virus induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV-1 3B infected in human MT-4 cells assessed as protection against virus induced cytopathic effect after 5 days by MTT assay	[PMID: 27647368]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 27750153]
MT4	CC₅₀	>15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 28254696]
MT4	CC₅₀	>15 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 28314514]
MT4	CC₅₀	>15 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 28314598]
MT4	CC₅₀	>0.015 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	[PMID: 28481112]
MT4	CC₅₀	>15.02 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 28559060]
MT4	CC₅₀	>18776 nM Compound: NVP	Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay	[PMID: 28628334]
MT4	CC₅₀	>15.02 μM Compound: NVP	Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 28987601]
MT4	CC₅₀	>15.02 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 29291935]
MT4	CC₅₀	>4000 nM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 29353724]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against human MT4 cells after 5 days by MTT assay Cytotoxicity against human MT4 cells after 5 days by MTT assay	[PMID: 29534929]
MT4	CC₅₀	>15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 29559197]
MT4	CC₅₀	>15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 29635166]
MT4	CC₅₀	>15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 29670703]
MT4	CC₅₀	>4 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	[PMID: 30318436]
MT4	CC₅₀	>7000 nM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 30525601]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 30721060]
MT4	CC₅₀	>15.03 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay	[PMID: 31421633]
MT4	CC₅₀	>15.03 μM Compound: 1; NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 31434039]
MT4	CC₅₀	>15.03 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 31714780]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 31735575]
MT4	CC₅₀	>4.6 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay	[PMID: 31767136]
MT4	CC₅₀	>15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 32197813]
MT4	EC₅₀	0.18 μM Compound: NVP	Antiviral activity against HIV1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 32197813]
MT4	CC₅₀	>9.51 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 32200201]
MT4	CC₅₀	>15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 32712537]
MT4	CC₅₀	>18776 nM Compound: NVP	Cytotoxicity against human MT-4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT-4 cells assessed as reduction in cell viability by MTT assay	[PMID: 32883642]
MT4	CC₅₀	>15 μM Compound: 1; NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 32977301]
MT4	CC₅₀	>15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 33279288]
MT4	CC₅₀	>9.5 μM Compound: 1; NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	[PMID: 33340914]
MT4	CC₅₀	>15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 33567378]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against in human MT-4 cells after 5 days by MTT assay Cytotoxicity against in human MT-4 cells after 5 days by MTT assay	[PMID: 33851529]
MT4	CC₅₀	>15.02 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	[PMID: 33979774]
MT4	CC₅₀	>15.03 μM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells incubated for 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells incubated for 5 days by MTT assay	[PMID: 34090079]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against mock infected human MT4 cells by MTT assay Cytotoxicity against mock infected human MT4 cells by MTT assay	[PMID: 34197708]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	[PMID: 34403976]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 34432448]
MT4	CC₅₀	>15020 nM Compound: NVP	Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 34890994]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	[PMID: 35073089]
MT4	CC₅₀	>15.02 μM Compound: 1; NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 to 7 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 to 7 days by MTT assay	[PMID: 35640327]
MT4	CC₅₀	>15 μM Compound: Nevirapine	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 35649164]
MT4	CC₅₀	15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as cell growth inhibition incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell growth inhibition incubated for 5 days by MTT assay	[PMID: 35679690]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	[PMID: 35780636]
MT4	CC₅₀	>9.51 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability Cytotoxicity against human MT4 cells assessed as reduction in cell viability	[PMID: 36442370]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as cell growth inhibition incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as cell growth inhibition incubated for 5 days by MTT assay	[PMID: 36446205]
MT4	CC₅₀	>15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 36577220]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT spectrophotometric assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT spectrophotometric assay	[PMID: 36640458]
MT4	CC₅₀	>15.02 μM Compound: NPV	Cytotoxicity against human MT4 cells assessed as reduction in cell viability Cytotoxicity against human MT4 cells assessed as reduction in cell viability	[PMID: 36708678]
MT4	CC₅₀	>15.03 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 36996328]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 37255025]
MT4	CC₅₀	>15.02 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 37393790]
MT4	CC₅₀	>9.51 μM Compound: 1; NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 37536208]
MT4	CC₅₀	>951 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	[PMID: 37976805]
MT4	CC₅₀	>15.03 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 38996652]
MT4	CC₅₀	>15 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	[PMID: 39094273]
MT4	CC₅₀	>15.03 μM Compound: NVP	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT method Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT method	[PMID: 39167895]
MT4	CC₅₀	>80 μM Compound: Nevirapine	Tested for the cytotoxic concentration required to reduce the number of viable mock infected MT-4 cells Tested for the cytotoxic concentration required to reduce the number of viable mock infected MT-4 cells	[PMID: 7527463]
MT4	EC₅₀	>80 μM Compound: Nevirapine	Tested for the inhibitory activity of HIV-2 infected MT-4 cells Tested for the inhibitory activity of HIV-2 infected MT-4 cells	[PMID: 7527463]
MT4	EC₅₀	0.12 μM Compound: Nevirapine	Tested for the inhibitory activity of HIV-1 infected MT-4 cells Tested for the inhibitory activity of HIV-1 infected MT-4 cells	[PMID: 7527463]
MT4	IC₅₀	>10 μg/mL Compound: Nevirapine	Cytotoxicity against uninfected MT-4 cells Cytotoxicity against uninfected MT-4 cells	[PMID: 7538590]
MT4	IC₅₀	0.01 μg/mL Compound: Nevirapine	Antiviral activity against HIV-1 (strain RF) infected MT-4 cells Antiviral activity against HIV-1 (strain RF) infected MT-4 cells	[PMID: 7538590]
MT4	IC₅₀	0.22 μg/mL Compound: Nevirapine	Antiviral activity against HIV-1 resistant to 2-(2-Benzoyl-4-chloro-phenyl)-N-[4-(3-dimethylamino-propoxy)-2-methyl-phenyl]-acetamide in MT-4 cells Antiviral activity against HIV-1 resistant to 2-(2-Benzoyl-4-chloro-phenyl)-N-[4-(3-dimethylamino-propoxy)-2-methyl-phenyl]-acetamide in MT-4 cells	[PMID: 7538590]
MT4	CC₅₀	290 μM Compound: Nevirapine	Cytotoxic concentration based on the reduction of viability of mock-infected cells Cytotoxic concentration based on the reduction of viability of mock-infected cells	[PMID: 7540208]
MT4	EC₅₀	0.073 μM Compound: Nevirapine	Compound was evaluated for the inhibition of HIV-1 induced CPE (HTLV-III B strain ) replication in MT-4 cells Compound was evaluated for the inhibition of HIV-1 induced CPE (HTLV-III B strain ) replication in MT-4 cells	[PMID: 7540208]
MT4	CC₅₀	>376 μM Compound: Nevirapine	Compound dose required to reduce the viability of mock-infected cells by 50% Compound dose required to reduce the viability of mock-infected cells by 50%	[PMID: 7650679]
MT4	EC₅₀	0.3 μM Compound: Nevirapine	Dose required to achieve 50% protection of MT-4 cells from HIV-1 induced cytopathogenicity Dose required to achieve 50% protection of MT-4 cells from HIV-1 induced cytopathogenicity	[PMID: 7650679]
MT4	CC₅₀	<300 μM Compound: Nevirapine	Concentration required to reduce the viability of mock-infected MT-4 cells by 50% Concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 8558522]
MT4	EC₅₀	0.3 μM Compound: Nevirapine	Effective concentration against HIV-1 induced cytopathogenicity in MT-4 cells Effective concentration against HIV-1 induced cytopathogenicity in MT-4 cells	[PMID: 8558522]
MT4	ED₅₀	>10 μM Compound: nevirapine	Inhibition of HIV-1(IIIB) variants (Ile100/Cys181) in HIV-1 MT-4 cells Inhibition of HIV-1(IIIB) variants (Ile100/Cys181) in HIV-1 MT-4 cells	[PMID: 8863804]
MT4	ED₅₀	0.15 μM Compound: nevirapine	Tested for the inhibition of wild type HIV-1 (IIIB) replication in MT-4 cells Tested for the inhibition of wild type HIV-1 (IIIB) replication in MT-4 cells	[PMID: 8863804]
MT4	ED₅₀	0.62 μM Compound: nevirapine	Inhibition of mutant type (Ile100) HIV-1 (IIIB) replication in MT-4 cells Inhibition of mutant type (Ile100) HIV-1 (IIIB) replication in MT-4 cells	[PMID: 8863804]
MT4	ED₅₀	22 μM Compound: nevirapine	Inhibition of mutant type (Cys181) HIV-1 (IIIB) replication in MT-4 cells Inhibition of mutant type (Cys181) HIV-1 (IIIB) replication in MT-4 cells	[PMID: 8863804]
MT4	ED₅₀	8 μM Compound: nevirapine	Inhibition of HIV-1(IIIB) variants (Ile100/Asn103) in HIV-1 MT-4 cells Inhibition of HIV-1(IIIB) variants (Ile100/Asn103) in HIV-1 MT-4 cells	[PMID: 8863804]
MT4	CC₅₀	>300 μM Compound: nevirapine	Dose required to reduce the viability of mock-infected cells by 50% Dose required to reduce the viability of mock-infected cells by 50%	[PMID: 9154967]
MT4	EC₅₀	>100 μM Compound: nevirapine	Inhibitory activity against resistant HIV-1 strain NevR was determined. Inhibitory activity against resistant HIV-1 strain NevR was determined.	[PMID: 9154967]
MT4	EC₅₀	0.25 μM Compound: nevirapine	Dose required to achieve 50% protection of MT-4 cells from the HIV-1 induced cytopathogenicity in mock-infected MT-4 cells Dose required to achieve 50% protection of MT-4 cells from the HIV-1 induced cytopathogenicity in mock-infected MT-4 cells	[PMID: 9154967]
MT4	EC₅₀	0.31 μM Compound: nevirapine	Inhibitory activity against resistant HIV-1 strain MC639r was determined. Inhibitory activity against resistant HIV-1 strain MC639r was determined.	[PMID: 9154967]
MT4	CC₅₀	683 μM Compound: Nevirapine	Dose required to reduce the viability of mock-infected cells by 50%, determined by MTT method. Dose required to reduce the viability of mock-infected cells by 50%, determined by MTT method.	[PMID: 9767646]
MT4	EC₅₀	0.03 μM Compound: Nevirapine	Dose required to achieve 50% protection of MT-4 cells from HIV-1(IIIB) induced cytopathogenicity, determined by MIT method. Dose required to achieve 50% protection of MT-4 cells from HIV-1(IIIB) induced cytopathogenicity, determined by MIT method.	[PMID: 9767646]
MT4	ED₅₀	0.62 μM Compound: Nevirapine	Antiviral activity was determined against HIV-1 (clone 118) in MT-4 cells infected with HIV-1 IIIB using an XTT assay Antiviral activity was determined against HIV-1 (clone 118) in MT-4 cells infected with HIV-1 IIIB using an XTT assay	[PMID: 9873380]
MT4	ED₅₀	22 μM Compound: Nevirapine	Antiviral activity was determined against HIV-1 (clone 90) in MT-4 cells infected with HIV-1 IIIB using an XTT assay Antiviral activity was determined against HIV-1 (clone 90) in MT-4 cells infected with HIV-1 IIIB using an XTT assay	[PMID: 9873380]
MT4	CC₅₀	>15.02 μM Compound: NVP	Cytotoxicity against Homo sapiens (human) MT4 cells by MTT assay Cytotoxicity against Homo sapiens (human) MT4 cells by MTT assay	10.1007/s00044-009-9220-x
MT4	EC₅₀	0.208 μM Compound: NVP	Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity after 4 days by MTT assay	10.1007/s00044-009-9220-x
MT4	CC₅₀	>4 μg/mL Compound: Nevirapine	Cytotoxicity against Homo sapiens (human) MT4 cells Cytotoxicity against Homo sapiens (human) MT4 cells	10.1007/s00044-011-9662-9
MT4	EC₅₀	>4 μg/mL Compound: Nevirapine	Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected human MT4 cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected human MT4 cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
MT4	EC₅₀	0.05 μg/mL Compound: Nevirapine	Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
MT4	CC₅₀	>4 μg/mL Compound: Nevirapine	Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay	10.1007/s00044-011-9664-7
MT4	EC₅₀	0.05 μg/mL Compound: Nevirapine	Antiviral activity against Human immunodeficiency virus 1 IIIB infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 IIIB infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	10.1007/s00044-011-9664-7
MT4	EC₅₀	4 μg/mL Compound: Nevirapine	Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	10.1007/s00044-011-9664-7
MT4	CC₅₀	>4 μg/mL Compound: Nevirapine	Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay	10.1007/s00044-011-9705-2
MT4	EC₅₀	>4 μg/mL Compound: Nevirapine	Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	10.1007/s00044-011-9705-2
MT4	EC₅₀	0.05 μg/mL Compound: Nevirapine	Antiviral activity against Human immunodeficiency virus 1 IIIB infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 IIIB infected MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	10.1007/s00044-011-9705-2
MT4	CC₅₀	>4 μg/mL Compound: Nevirapine	Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay Cytotoxicity against Homo sapiens (human) MT4 cells after 4 days by MTT assay	10.1007/s00044-011-9776-0
MT4	EC₅₀	>4 μg/mL Compound: Nevirapine	Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	10.1007/s00044-011-9776-0
MT4	EC₅₀	0.05 μg/mL Compound: Nevirapine	Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	10.1007/s00044-011-9776-0
MT4	CC₅₀	>4 μg/mL Compound: Nevirapine	Cytotoxicity against Homo sapiens (human) MT4 cells after 5 days by MTT assay Cytotoxicity against Homo sapiens (human) MT4 cells after 5 days by MTT assay	10.1007/s00044-012-0129-4
MT4	IC₅₀	>0.05 μg/mL Compound: Nevirapine	Antiviral activity against Human immunodeficiency virus 1 IIIB infected MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against Human immunodeficiency virus 1 IIIB infected MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay	10.1007/s00044-012-0129-4
MT4	CC₅₀	>4 μg/mL Compound: BOE, BIRG587	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	10.1007/s00044-013-0567-7
MT4	IC₅₀	>4 μg/mL Compound: BOE, BIRG587	Antiviral activity against HIV2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV2 ROD infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	10.1007/s00044-013-0567-7
MT4	IC₅₀	0.05 μg/mL Compound: BOE, BIRG587	Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay Antiviral activity against HIV1 3B infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	10.1007/s00044-013-0567-7
MT4	CC₅₀	>200 μM Compound: nevirapine	Concentration required to reduce the viability of mock-infected MT-4 cells by 50% Concentration required to reduce the viability of mock-infected MT-4 cells by 50%	10.1016/S0960-894X(97)00340-5
MT4	EC₅₀	0.25 μM Compound: nevirapine	Concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 Concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1	10.1016/S0960-894X(97)00340-5
MT4	CC₅₀	>15.02 μM Compound: NVP	Cytotoxicity against HIV-1 3B mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against HIV-1 3B mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay	10.1039/C3MD00028A
MT4	CC₅₀	>15.02 μM Compound: NVP	Cytotoxicity against HIV-2 ROD mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against HIV-2 ROD mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay	10.1039/C3MD00028A
MT4	EC₅₀	0.09 μM Compound: NVP	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	10.1039/C3MD00028A
MT4	CC₅₀	>15.02 μM Compound: NVP	Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability measured 5 days post-infection by MTT assay Cytotoxicity against mock-infected human MT4 cells assessed as decrease in cell viability measured 5 days post-infection by MTT assay	10.1039/C3MD00247K
MT4	EC₅₀	0.11 μM Compound: NVP	Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay	10.1039/C3MD00247K
MT4	EC₅₀	5.12 μM Compound: NVP	Antiviral activity against HIV-1 RES056 harboring RT K103N+Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay Antiviral activity against HIV-1 RES056 harboring RT K103N+Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post-infection by MTT assay	10.1039/C3MD00247K
PBMC	CC₅₀	40.88 μg/mL Compound: NEV	Cytotoxicity against PHA-stimutated human PBMC after 24 hrs by MTS assay Cytotoxicity against PHA-stimutated human PBMC after 24 hrs by MTS assay	[PMID: 21334901]
PBMC	CC₅₀	>100 μM Compound: NVP	Cytotoxicity against HIV1 infected human PBMC cells assessed as reduction in cell viability after 7 days by MTT assay Cytotoxicity against HIV1 infected human PBMC cells assessed as reduction in cell viability after 7 days by MTT assay	[PMID: 27390064]
PBMC	IC₅₀	0.04 μM Compound: NVP	Antiviral activity against HIV-1 Bal infected in human PBMC by MTS assay Antiviral activity against HIV-1 Bal infected in human PBMC by MTS assay	[PMID: 28442262]
PBMC	CC₅₀	1003 μM Compound: Nevirapine	Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 5 days by MTT assay Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 5 days by MTT assay	[PMID: 31557609]
PBMC	CC₅₀	>10 μM Compound: Nevirapine	Cytotoxic concentration against PBMC cells Cytotoxic concentration against PBMC cells	[PMID: 7684450]
T-cell	IC₅₀	40 nM Compound: Nevirapine	Antiviral activity against HIV1 infected in 8186 T cells Antiviral activity against HIV1 infected in 8186 T cells	[PMID: 18800765]
TZM	CC₅₀	76.13 μg/mL Compound: Nevirapine	Cytotoxicity in human TZM-bl cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity in human TZM-bl cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 21982685]
TZM	CC₅₀	204.003 μM Compound: NVP	Cytotoxicity against human TZM-bl cells Cytotoxicity against human TZM-bl cells	[PMID: 23540737]
TZM	CC₅₀	76.13 μM Compound: NVP	Cytotoxicity against human TZM-bl cells after 48 hrs by MTT assay Cytotoxicity against human TZM-bl cells after 48 hrs by MTT assay	[PMID: 24794742]
TZM	CC₅₀	>50 μM Compound: Nevirapine	Cytotoxicity against human TZM-bl cells assessed as cell viability after 48 hrs by WST1 assay Cytotoxicity against human TZM-bl cells assessed as cell viability after 48 hrs by WST1 assay	[PMID: 25199582]
TZM	CC₅₀	204.003 μM Compound: NVP	Cytotoxicity against human TZM-bl cells after 3 days by XTT assay Cytotoxicity against human TZM-bl cells after 3 days by XTT assay	[PMID: 25468035]
TZM	CC₅₀	>100 μM Compound: Nevirapine	Cytotoxicity against human TZM-bl cells assessed as reduction of cell viability after 48 hrs Cytotoxicity against human TZM-bl cells assessed as reduction of cell viability after 48 hrs	[PMID: 27108399]
TZM	CC₅₀	>15000 nM Compound: 1; NVP	Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability measured after 1 day by CytoTox-Glo assay Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability measured after 1 day by CytoTox-Glo assay	[PMID: 33340914]
U2OS	CC₅₀	>100 μM Compound: Nevirapine	Cytotoxicity against human U2OS cells assessed as reduction of cell viability after 48 hrs Cytotoxicity against human U2OS cells assessed as reduction of cell viability after 48 hrs	[PMID: 27108399]
U2OS	IC₅₀	0.42 μM Compound: Nevirapine	Antiviral activity against HIV1 virus-like particles harboring wild type reverse transcriptase infected in human U2OS cells after 24 hrs by Renilla luciferase assay Antiviral activity against HIV1 virus-like particles harboring wild type reverse transcriptase infected in human U2OS cells after 24 hrs by Renilla luciferase assay	[PMID: 27108399]
Vero	CC₅₀	27.1 μM Compound: nevirapine	Toxicity in African green monkey Vero cells Toxicity in African green monkey Vero cells	[PMID: 20050672]
Vero	IC₅₀	>100 μg/mL Compound: Nevirapine	Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 24 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 24 hrs by MTT assay	[PMID: 27105027]
Vero	CC₅₀	>100 μM Compound: NVP	Cytotoxicity against HIV1 infected African green monkey Vero cells assessed as reduction in cell viability after 7 days by MTT assay Cytotoxicity against HIV1 infected African green monkey Vero cells assessed as reduction in cell viability after 7 days by MTT assay	[PMID: 27390064]

In Vitro

Nevirapine itself is an inhibitor of only CYP3A4 at concentrations that are well above those of therapeutic relevance (K_i=270 μM)^[1]. Nevirapine has been used as a re-differentiation agent to treat cancers in several human cancer models. At all doses (100, 200, 350, 500 μM) tested, nevirapine significantly inhibits cell proliferation after 48 h treatment. At high dose (500 μM), nevirapine significantly increases the percentage of apoptotic cells compared with control^[2]. Nevirapine is a potent and selective inhibitor (IC₅₀=10-100 nM) of the replication of a wide variety of HIV-1 strains in several cellular assays^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Nevirapine is available for use in combination with nucleoside HIV-1 reverse transcriptase inhibitors (e.g., zidovudine, didanosine, etc.). Nevirapine has received FDA approval for use in combination with HIV-1 protease inhibitors (e.g., saquinavir, ritonavir, indinavir, etc.). In humans, nevirapine is eliminated primarily in the urine as glucuronide conjugates of 2-, 3-, 8-, and 12-hydroxynevirapine^[1]. Nevirapine is completely absorbed in both sexes of mouse, rat, rabbit, monkey, and chimpanzee. Nevirapine is extensively metabolized in both sexes of all animal species studied^[4]. Nevirapine (9 mg/kg, 18 mg/kg and 36 mg/kg) shows significant reduction in ulcer severity score and ulcer index as compared to the control^[5]

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ensayo clínico

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

No. CAS 129618-40-2
Appearance Solid
Peso molecular 266.30
Fòrmula C₁₅H₁₄N₄O
Color White to off-white
SMILES

O=C1C2=C(N=CC=C2)N(C3CC3)C4=NC=CC(C)=C4N1
Synonyms

BI-RG 587; NSC 641530; NVP
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (8)

All Bio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Phytomedicine

Wikstrol B reactivates latent human immunodeficiency virus (HIV-1) via the nuclear factor-κB (NF-κB) pathway. [Abstract]

2025 Jun:141:156667. PMID: 40233507
Proc Natl Acad Sci U S A

Human endogenous retrovirus-K (HERV-K) reverse transcriptase (RT) structure and biochemistry reveals remarkable similarities to HIV-1 RT and opportunities for HERV-K-specific inhibition. [Abstract]

2022 Jul 5;119(27):e2200260119. PMID: 35771941
Cell Rep

MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity. [Abstract]

2021 Mar 2;34(9):108808. PMID: 33657372
Int J Antimicrob Agents

Efficacy of antiretroviral compounds against Toxoplasma gondii in vitro. [Abstract]

2019 Dec;54(6):814-819. PMID: 31479744
Virol Sin

Development of a reporter HBoV1 strain for antiviral drug screening and life cycle studies. [Abstract]

2025 Mar 25:S1995-820X(25)00031-8. PMID: 40147635

Nevirapine purchased from MedChemExpress. Usage Cited in: Virol Sin. 2025 Mar 25:S1995-820X(25)00031-8. [Abstract]

Nevirapine (50 μM; 72 h) displayed ∼50% inhibition efficiency against luciferase activity in HEK293T cells were transfected with pHBoV1-HiBiTNS1.
Biotechnol Bioeng

An integrated biomimetic array chip for establishment of collagen-based 3D primary human hepatocyte model for prediction of clinical drug-induced liver injury. [Abstract]

2021 Dec;118(12):4687-4698. PMID: 34478150
Drug Metab Dispos

The strong clinical interaction between bupropion and CYP2D6 is primarily mediated through bupropion metabolites and their stereoisomers: A paradigm for evaluating metabolites in drug-drug interaction risk. [Abstract]

2025 May;53(5):100070. PMID: 40245579
Res Sq

2026 Apr 21.

Solvente y solubilidad

In Vitro:

DMSO : 14.29 mg/mL (53.66 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.7552 mL

18.7758 mL

37.5516 mL

5 mM

0.7510 mL

3.7552 mL

7.5103 mL

10 mM

0.3755 mL

1.8776 mL

3.7552 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.43 mg/mL (5.37 mM); Clear solution

This protocol yields a clear solution of ≥ 1.43 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (14.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.43 mg/mL (5.37 mM); Clear solution

This protocol yields a clear solution of ≥ 1.43 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (14.3 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocolo

Cell Assay^[2]

FRO cells are seeded into 96-well culture plates at 10,000 cells/well. Cells are treated with different doses of nevirapine (0, 100, 200, 350 and 500 μM) for 48 h. MTT dye (5 mg/mL) is added to each well for additional 4 h, and the reaction is then stopped by the addition of DMSO. Optical density is measured at 490 nm on a multi-well plate reader^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[4]

Rats: Nevirapine and [¹⁴C] Nevirapine are dissolved together in absolute ethanol and methylene chloride (1:1, v/v) with mild heating. The concentration of drug in suspension is 2 mg/mL (20 mg/kg, 26 μCi) for oral dosing to rats and 6.7 mg/mL (20.3 mg/kg, 10 μCi males, 8.9 μCi females) for intraduodenal administration to rats before bile collection. The i.v. dose is administered to rats (1.1 mg/kg, 20 μCi) as a solution in 20% ethanol/80% saline^[4].

Mice: Nevirapine and [¹⁴C] Nevirapine are dissolved together in absolute ethanol and methylene chloride (1:1, v/v) with mild heating. The concentration of drug in suspension is 2 mg/mL (20 mg/kg, 2.5 μCi) with a specific activity of 5.55 μCi/mg for oral dosing to mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (288 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Erickson DA, et al. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitornevirapine by human hepatic cytochromes P-450. Drug Metab Dispos. 1999 Dec;27(12):1488-95. [Content Brief]

[2]. Dong JJ, et al. In vitro evaluation of the therapeutic potential of nevirapine in treatment of human thyroid anaplastic carcinoma. Mol Cell Endocrinol. 2013 May 6;370(1-2):113-8. [Content Brief]

[3]. Merluzzi VJ, et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science. 1990 Dec 7;250(4986):1411-3. [Content Brief]

[4]. Riska PS, et al. Biotransformation of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, in mice, rats, rabbits, dogs, monkeys, and chimpanzees. Drug Metab Dispos. 1999 Dec;27(12):1434-47. [Content Brief]

[5]. Onasanwo SA, et al. Evaluation of anti-ulcerogenic and ulcer-healing activities of nevirapine in rats. Afr J Med Med Sci. 2015 Sep;44(3):251-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.7552 mL	18.7758 mL	37.5516 mL	93.8791 mL
	5 mM	0.7510 mL	3.7552 mL	7.5103 mL	18.7758 mL
	10 mM	0.3755 mL	1.8776 mL	3.7552 mL	9.3879 mL
	15 mM	0.2503 mL	1.2517 mL	2.5034 mL	6.2586 mL
	20 mM	0.1878 mL	0.9388 mL	1.8776 mL	4.6940 mL
	25 mM	0.1502 mL	0.7510 mL	1.5021 mL	3.7552 mL
	30 mM	0.1252 mL	0.6259 mL	1.2517 mL	3.1293 mL
	40 mM	0.0939 mL	0.4694 mL	0.9388 mL	2.3470 mL
	50 mM	0.0751 mL	0.3755 mL	0.7510 mL	1.8776 mL

Keywords

Nevirapine

8 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Nevirapine

Anti-Infection Compound Library

FDA-Approved Drug Library

Antiviral Compound Library

CNS-Penetrant Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Antiparasitic Compound library

Rare Diseases Drug Library

Pediatric Drug Library

EMA-Approved Drug Library

Human Metabolite Library

Heterocyclic Compound Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Nevirapine

Ver todos los productos específicos de isoformas HIV

Ver todos los productos específicos de isoformas Parasite

Actividad biológica

Chemical Information

Publications (8)

Solvente y solubilidad

Protocolo

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Nevirapine

Anti-Infection Compound Library

FDA-Approved Drug Library

Antiviral Compound Library

CNS-Penetrant Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Antiparasitic Compound library

Rare Diseases Drug Library

Pediatric Drug Library

EMA-Approved Drug Library

Human Metabolite Library

Heterocyclic Compound Library

Off-patent Drug Library

Mitochondrial Toxicity Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Nevirapine

Ver todos los productos específicos de isoformas HIV

Ver todos los productos específicos de isoformas Parasite

Actividad biológica

Chemical Information

Publications (8)

Solvente y solubilidad

Protocolo

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Nevirapine Related Classifications

HY-10570 Related Classifications